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INTRODUCTION
Congenital diaphragmatic hernia (CDH) is a developmental defect of the lungs en 
diaphragm that occurs in 1 per 4000-4500 live births (1). In the Netherlands, approximately 
40 patients with CDH are born alive each year. 
The first description of diaphragmatic hernia was made by Ambroise Paré in 1575 (2). 
However, these cases were caused by trauma. CDH in a newborn was first reported in 1754 
by George Macaulay, in an infant who died of respiratory failure soon after birth (3). In 
1769 Giovanni Morgagni first described the parasternal hernia, now known as Morgagni 
hernia (4). Almost 100 years later, in 1848, Bochdalek described the posterolateral hernia; 
the Bochdalek hernia, and already recognized the importance of lung hypoplasia (5). 
The Morgagni hernia is rare, consisting of only 3-5% of all CDH cases. Its diagnosis is 
often delayed, with patients presenting with nonspecific respiratory and gastrointestinal 
symptoms in infancy or even adulthood (6). However, herniation of the abdominal content 
with strangulation, bowel ischemia and perforation may occur (7). 
The posterolateral, or Bochdalek hernia is seen in more than 90% of the cases, and can 
present left-sided, right-sided or bilateral. Also, instead of a true defect, an eventration or 
hernial sac can be present. From the early embryological phase onwards, the development 
of the diaphragm, both lungs and its vasculature is altered. This results in varies degrees of 
pulmonary hypoplasia and pulmonary hypertension (PH) (8). The defect in the diaphragm 
ranges from small defects to complete agenesis of mostly the left diaphragm. The 
exact etiology of CDH remains unknown and seems to be multifactorial (figure 1). It is 
also unknown why the diaphragm defects mainly occur on the left side, in a ratio of 8:1 
compared to the right sided defects (9). 
Mortality was very high before the introduction of surgery, and it was only at the beginning 
of the last century that surgery was considered a therapeutic option, decreasing mortality 
to approximately 85-50% (11, 12). Although Korns already recognized the importance of 
PH in 1921, it wasn’t until the late 1980’s that preoperative cardiopulmonary stabilization 
and delayed surgery became standard of care, further improving outcome (11, 13, 14). 
Nowadays, with the introduction of standardized care, mortality and morbidity has 
further decreased, with a survival of approximately 73% in well-established centers of 
expertise (15). Apart from the experience of the treatment teams, mortality and morbidity 
are now highly dependent on the severity of lung hypoplasia, the presence of PH, and the 
presence of associated anomalies, such as chromosomal and cardiac anomalies (1, 15, 16). 
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Figure 1. Schematic overview of the etiological factors, the natural history and therapeutic 
options of CDH (10).
PREDICTION
Prenatal parameters
In countries with routine prenatal ultrasound screening, CDH is most often diagnosed 
prenatally. The introduction of the second trimester ultrasound has increased the detection 
of congenital anomalies such as CDH considerably (17, 18). Several prenatal ultrasound 
parameters have been developed to prognosticate postnatal outcome in patients 
with CDH. Prenatal prediction can guide parents and caretakers in decisions regarding 
continuation of pregnancy and the use of prenatal therapy such as foetal endoscopic 
tracheal occlusion (FETO). It has also been used to compare patient populations and 
management strategies. One of the first ultrasound parameters that was used to predict 
lung hypoplasia and survival is the Lung-to-Head Ratio (LHR). To calculate the LHR, the 
contralateral lung is measured, using two perpendicular linear measurements. These 
measurements are multiplied and divided by the head circumference. However, the LHR 
was not found to be very reliable, as lung growth is not linear to head growth during 
pregnancy (19). Subsequently, the observed-to-expected Lung-to-Head Ratio (O/E LHR) 
was developed, comparing the observed LHR to the expected LHR appropriate for the 
age of the fetus. When using the tracing method, tracing the contours of the lung, this is 
a fairly reliable parameter with a small inter observer variability (20). When using MRI to 
evaluate the lung size, observed-to-expected total fetal lung volume (TFLV) is possibly a 
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more accurate predictor of survival, but operator experience in measurement of the lung 
volumes plays a role in its predicting value (21, 22). 
Another prenatal predictor for postnatal outcome in patients with CDH is the position of 
the liver, evaluated on ultrasound or MRI. Intrathoracic position of the liver is associated 
with an increased risk of mortality and the need for extracorporeal membrane oxygenation 
(23, 24). Also the position of the stomach has been evaluated as a predictor for outcome 
(25, 26). However, one should be aware that all prenatal parameters can be used to predict 
lung hypoplasia, but do not reliably predict PH decreasing its sensitivity for adverse 
outcome (27, 28). 
Also, to predict outcome, the presence of genetic or other major congenital anomalies 
plays a substantial role. Genetic anomalies can often be found with a micro-array or 
increasingly with next generation sequencing, for major anomalies the structural fetal 
ultrasound is used. The prevalence of these anomalies varies widely, depending on the 
population under evaluation. Prenatally, these anomalies are seen in approximately 34% 
of fetuses with CDH; 25% has associated anomalies such as cardiac, urinary tract, limb and 
central nervous system anomalies, 11% has chromosomal anomalies, genetic syndromes 
or microdeletions (1). A large part of the genetic anomalies are explained by de novo 
mutations (29). These anomalies are an important predictor for adverse outcome. In the 
prenatal period because of intrauterine fetal demise or termination of pregnancy, but also 
in the neonatal period mortality is high in this group of CDH patients (1, 30, 31). 
Postnatal parameters
Postnatal models to predict morbidity and mortality has the potential to help care 
providers to start the right treatment in the right patient at the right time. It could prevent 
over and under treatment and early therapy can possibly prevent exacerbation of PH. For 
these postnatal predictions, there are several prediction models and variables such as 
SNAP II score, highest PaO2 minus highest PaCO2, and oxygenation index. However, many 
are based on relatively small groups of patients, are difficult to apply or have not been 
externally validated (32-36). Brindle et al, and the Congenital Diaphragmatic Hernia Study 
Group (CDHSG) have developed a simple and validated early clinical prediction rule in a 
large cohort of patients to identify low (<10%), intermediate (~20%), and high risk (~50%) 
of death. This model is based on birth weight, 5-minute Apgar score, severe PH, and the 
presence of cardiac and chromosomal anomalies (37). 
The predicted value of this postnatal model has been favorable compared to prenatal 
predictors (38). One could argue that combining post- and prenatal risk factors within 
a single prediction model could further improve the significance of a prediction model. 
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However, prenatal and postnatal predictors have only been integrated in one prediction 
model in a small group of patients from a single center (39). 
Biomarkers
Instead of clinical parameters, biochemical biomarkers might serve as better predictive 
markers of outcome. Biomarkers are defined as “a characteristic that is objectively 
measured and evaluated as an indicator of normal biological processes, pathogenic 
processes, or pharmacologic responses to a therapeutic intervention” (40). Sensitive and 
specific biomarkers, preferably taken early, for instance plasma from the umbilical cord, 
could play a major role in the development of patient specific treatment algorithms. 
Although biomarkers are not routinely used, many have been tested in CDH animal models 
and some have been evaluated for its role in patients with CDH. An increased level of 
plasma vascular endothelial growth factor A (VEGFA), which is associated with embryonic 
vascular development amongst others, and a decreased level of placental growth factor, 
have been found to predict clinical severity of pulmonary vascular disease and mortality 
in CDH patients (41). The soluble receptor for advanced glycation end products (sRAGE) 
is a known marker for endothelial function, and Kipfmueller et al found it to be an early 
biomarker for the need of extracorporeal membrane oxygenation (ECMO) in CDH cases 
(42). Cytokines, involved in the systemic inflammatory response, have been proven 
to be elevated in patients with CDH, some already in utero, and its increase is directly 
related to disease severity (43, 44). Herrera-Rivero et al. evaluated the use of microRNA 
as biomarkers and found a dysregulation of microRNA participating in the transforming 
growth factor beta (TGF-β) signaling pathway in patients who developed CLD or died. 
This pathway plays an important role in lung development, especially in alveolarisation 
and tissue homeostasis. Also microRNA involved in the semaphoring signaling, important 
for development and regulation of immune responses, was dysregulated in this group of 
patients (45). 
However, these potential biomarkers were only tested in small groups of patients in single 
centers and causality is hard to prove. Some biomarkers have been tested within a large 
multicenter trial of patients with CDH, the VICI trial, with less success (15). High-sensitivity 
troponin T (HsTnT) and N-terminal pro-brain natriuretic peptide (NT-proBNP) did not 
predict morbidity or mortality, although both have been proven to have a predictive 
value in cardiovascular diseases (46).  Other presumed biomarkers such as tracheal 
sphingolipids, mediators involved in lung development, injury and repair, did not predict 
chronic lung disease or death in this population either (47). 
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TREATMENT
The CDH EURO Consortium is a well-established consortium of expertise centers in and 
outside Europe, that developed and revised standardized neonatal treatment guidelines 
based on clinical evidence and expert opinion (48, 49). They also collaborated in 
multicenter research such as the VICI trial (15). Since 2008, all patients with CDH, born in 
a center of the CDH EURO Consortium, are treated according to these guidelines. In 2018, 
the Canadian Congenital Diaphragmatic Hernia Collaborative developed a guideline for 
CDH care with similar conclusions, and similar low level of evidence (50).  
Most children with CDH develop severe cardiorespiratory distress immediately after birth 
(51-53). As stated in the consensus guidelines, the key principle during the first days 
of life is avoiding high airway pressures whilst establishing adequate oxygenation and 
cardiovascular stability (48). Consequently, all infants are routinely intubated immediately 
after birth, followed by gentle ventilation to prevent ventilator induced lung injury 
(VILI). PH is treated with oxygen, sedation, blood pressure support and, if needed, with 
inhalational or systemic vasodilator agents (48, 50, 54, 55). Only after pulmonary and 
cardiovascular stabilisation, surgical repair of the diaphragmatic defect is performed. PH, 
severe lung hypoplasia and VILI are the most important risk factors for poor outcome (51, 
56, 57). Therefore, it might be safer to apply an individualized and conservative approach, 
allowing the minority of newborns with good prenatal predictive parameters to breath 
spontaneously at birth, as prenatal parameters can predict the severity of lung hypoplasia, 
and VILI is associated with worse outcome in CDH patients.   
The physiologic pulmonary vascular transition of the neonate after birth takes time, 
sometimes even weeks, to achieve normal values of pulmonary arterial pressure. In 
children with CDH the pulmonary vascular resistance often does not drop adequately 
due to altered development of the pulmonary vasculature and a reduced vascular 
bed. The pulmonary vasculature in CDH patients is characterized by increased medial 
and adventitial wall thickness, but also an increase in vasoconstriction and vascular 
reactivity (58). Three main pathways are known to influence the vascular reactivity and 
are in principle accessible for pharmacological therapy: the endothelin pathway, and the 
prostacyclin pathway, and the nitric oxide-cGMP pathway [12]. 
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Figure 2. Three major pathways influencing pulmonary hypertension (59)
Targeted pharmacological therapy includes three classes of drugs based on these 
pathways. Drugs influencing the endothelin pathway are the endothelin receptor 
antagonists bosentan, ambrisentan and macitentan. These drugs only have an oral 
dosage form, because of their inability to be dissolved, and therefor are not suitable 
for the treatment of PH in newborns with CDH at birth. Pharmacotherapy influencing 
the prostacyclin pathway, such as prostacyclin derivates iloprost and treprostenil, can 
be given intravenously or via inhalation. Major disadvantage is their very short half-life 
with risk of rebound PH. Data are very limited but no randomized controlled trials (RCT) 
in infants with PH have shown superiority of these drugs, mainly compared to inhaled 
nitric oxide (iNO). Only retrospective data on small groups of CDH patients are available 
(59, 60). Currently, the selective phosphodiesterase type 3 (PDE3) inhibitor milrinone is 
investigated for its role in the treatment of PH in CDH patients (NCT02951130).   
 iNO and sildenafil both influence the nitric oxide-cGMP pathway. After inhalation, iNO 
diffuses rapidly across the alveolar-capillary membrane into the smooth muscle of 
pulmonary vessels and activates soluble guanylate cyclase. This enzyme mediates many 
of the biological effects of iNO and is responsible for the conversion of GTP to cGMP. The 
increase of intracellular concentrations of cGMP relaxes the smooth muscle via several 
mechanisms. iNO also causes bronchodilation, and has some anti-inflammatory and 
anti-proliferative properties (61). In patients with persistent pulmonary hypertension of 
the newborn (PPHN) iNO decreases the median duration of mechanical ventilation and 
reduces the need for ECMO. However, in the one available RCT in patients with CDH 
outcome did not improve, but was even slightly worse (62). Even though the positive 
pharmacodynamic effects in infants with CDH are much weaker than in infants with PPHN, 
in many centers iNO is standard of care in infants with CDH and PH (49, 63). 
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Sildenafil citrate is a selective phosphodiesterase type 5 (PDE5) inhibitor. PDE5 is an 
enzyme that specifically degrades cGMP. With the inhibitory effect of sildenafil on PDE5, 
it increases cGMP and enhances NO-mediated vasodilatation of the smooth muscles 
in vessels in and outside the lungs. Only 5 RCTs have been performed in a total of 166 
newborns, all with PPHN. These studies showed a decrease in oxygenation index (OI) and 
mortality when sildenafil was compared to placebo, however, when compared to another 
drug or when added to another drug, there was no significant reduction in mortality (64). 
Despite the lack of extensive research in large groups of infants, the use of sildenafil in 
the neonatal intensive care has increased substantially over the last decade (65). In CDH 
patients only retrospective data are available. A decrease in pulmonary vascular resistance 
index and an increase in cardiac output was found in a small group of oral sildenafil-
treated infants with CDH refractory to iNO (66). Intravenous sildenafil in CDH patients was 
associated with improved OI and the right-to-left shunt ratio over the PDA was reversed. 
However, a significant increase in vasopressor support was also seen (67, 68). This raises 
the question whether sildenafil is a better first line drug for the treatment for PH in CDH 
patients then iNO.  
When a CDH patient with PH is treated with oxygen, sedation, blood pressure support 
and vasodilator agents without adequate effect, ECMO can be considered. However, the 
benefit of ECMO treatment in CDH patients remains debated, as randomized controlled 
data in the era of standardized care are lacking (69, 70). However, it will only be beneficial in 
patients with reversibility of respiratory failure and PH. At this time, there is no prognostic 
tool to predict reversibility. The best timing of surgery on ECMO, early versus late versus 
after ECMO decannulation, is also controversial. Observational trials showed contrasting 
results (71). However, Dao et al. showed in a large cohort study that early repair, with a 
median time to repair of 2 days, is associated with improved survival, mainly due to a 
decrease of non-repaired patients (72).   
OUTCOME
Because survival in patients with CDH has improved substantially over time, morbidity 
and long-term follow-up has become a more important topic (73). Morbidity is influenced 
by the severity of lung hypoplasia and PH, but also by medical treatment and its potential 
iatrogenic sequelae. Although the relative contribution to iatrogenic damage is hard to 
quantify, infants with CDH are admitted to the intensive care and are subject to a multitude 
of invasive therapies. They are at risk for the development of chronic lung disease, 
chronic PH, but also gastroesophageal reflux disease, poor growth, recurrent infections 
and neurodevelopmental and neuropsychological sequelae (74). This underlines the 
important balance between the benefits of an invasive treatment and its burden. 
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CONCLUSION
Although mortality in patients with CDH has decreased significantly over time, it is 
still substantial. At the cost of increased survival multi organ morbidity is diagnosed 
increasingly, partly due to a more standardized long-term follow-up program that is in 
practice in many institutions nowadays (73). Better prenatal and postnatal prediction 
of outcome could help in developing a more individualized treatment plan, preventing 
under- and overtreatment and thus further improve outcome. Treatment options could 
then be tested in a specific subgroup of CDH patients. Right now, many treatment 
strategies in CDH patients are based on expert opinion, and iNO therapy as the first line 
treatment for PH in CDH patients might not be appropriate. In the search for a better 
therapeutic option the use of intravenous sildenafil might be promising.   
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AIMS AND OUTLINE OF THIS THESIS
Part I consists of the introduction of the disease CDH and explains the aim of this thesis 
to identify pre- and postnatal parameters and biochemical biomarkers to predict disease 
severity in CDH patients, and to evaluate different treatment modalities. 
Part II focuses on the prediction of mortality and morbidity using pre- and postnatal 
parameters as well as biomarkers. 
Chapter 2 describes the strength and weaknesses of preoperative chest radiographic 
thoracic area (CRTA) as a prediction tool, and evaluates its role compared to other 
prediction tools in the CDH population. 
In chapter 3 the CDHSG prediction rule is validated in the European population and 
additional prenatal predictive parameters are evaluated to further improve the model. 
The novel biomarkers SIGLEC-14, BCAM and ANGPTL3, predictive for bronchopulmonary 
dysplasia in preterm infants, are tested in CDH patients in chapter 4. 
Part III describes different treatment modalities and the possible individualization of 
treatment in CDH patients in the postnatal period. 
In chapter 5 a spontaneous breathing approach at birth in infants with good prenatal 
parameters is evaluated. 
Chapter 6 describes the pharmacokinetic modelling of intravenous sildenafil in newborns 
with CDH.
The CoDiNOS trial protocol, an international randomized controlled trial comparing 
intravenous sildenafil with iNO for the treatment of PH in CDH patients, is reported in 
chapter 7.
In part IV the results of the studies are discussed and placed in a broader perspective in 
chapter 8. In chapter 9 all results are summarized in English and Dutch.
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Congenital diaphragmatic hernia (CDH) is a developmental defect of the diaphragm 
and the lungs, resulting in pulmonary hypoplasia and abnormal pulmonary vasculature 
growth, causing pulmonary hypertension (PH) (1). CDH occurs in approximately one 
in 2500 live births and is associated with a reported mortality of approximately 27% in 
live-born patients (2). PH, severe lung hypoplasia and ventilator-induced lung injury are 
the most important risk factors for poor outcome in children with CDH (1). Prenatally, 
outcome prediction can guide parents and caretakers in decisions regarding termination 
of the pregnancy, the use of prenatal interventions such a temporary tracheal plugging 
(FETO), but also the use of specific postnatal therapy and the referral to high-volume 
centers for the delivery. Postnatally, an adequate early predictor can help parents to 
better understand the course of their child illness. Also, it can be used for severity based 
treatment, and standardized reporting and benchmarking between centers . 
In this issue of Pediatric Intensive Care Medicine, Dassios et al (3) show elegantly that 
measurement of the preoperative chest radiographic thoracic area (CRTA) in CDH 
infants can help to predict mortality. The authors suggest that CRTA is an easy tool, with 
a low inter- and intra-observer variation. It has a significant correlation with functional 
residual capacity in CDH patients, revealing the presence or absence of lung hypoplasia 
. In this single-centre retrospective cohort study, chest x-rays of 84 infants were used to 
calculate the CRTA. Dassios et al. found that CRTA is a better predictor of survival then 
the prenatally measured lung-to-head ratio (LHR). Interestingly, they did not compare 
CRTA with observed-to-expected (O/E) LHR, although O/E LHR has been proven to be 
more reliable as a prenatal predictor than LHR alone, because it is a more stable variable 
during pregnancy (4). Also, it would be interesting to test its role in predicting the need 
for extracorporeal membrane oxygenation (ECMO), although in this centre no ECMO 
treatment was offered. CRTA is a predictor of lung hypoplasia, but does not take PH into 
account, the other important risk factor for mortality. To be able to truly value the CRTA, 
external validation will be needed, as this is a single centre cohort with a large percentage 
of infants treated with foetal endoscopic tracheal occlusion (FETO), potentially creating a 
selection bias.
Although its role is not completely clear yet, CRTA measurement adds to the large group 
of postnatal and prenatal tools to predict outcome in this vulnerable group of patients. 
Over the years, many have already looked for the ”egg of Columbus”, both for prenatal and 
postnatal measures. The size of the defect seen during surgery is a very reliable predictor 
for outcome, but not suitable as a marker due to the timing of surgery (5). As the CDH 
registry repeatedly showed, a significant number of CDH newborns with a so-called 
type 4 diaphragmatic defect, are never operated. Therefor an earlier predictor is needed. 
Many prenatal measures have been used as a prediction tool. The most reliable are the 
O/E LHR, MRI estimates of foetal lung volume (FLV) and position of the liver and stomach 
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(6). But these tools are not perfect either. For instance, the O/E LHR has an area under 
the curve (AUC) of only 0.77% for survival (4). Right now, different O/E LHR measurement 
techniques at different time points in gestation are being used between centers, and there 
is a learning curve in the examination of the O/E LHR (7). The longest diameter method 
overestimates the O/E LHR up to 34% and has a larger inter observer variability then the 
tracing method (8). Standardization of the measurement of prenatal variables such as O/E 
LHR, is essential. Measuring lung volumes on MRI seems promising (6). However, in many 
centers it is not possible to use MRI for this purpose, due to unavailability and costs. Also, 
the power of a prediction tool is depending on the presence of the information needed. 
Prenatal data are not always available, due to data transfer problems, differences in health 
care organization, long travel distances or other reasons. 
A variety of postnatal tools have also been used to predict survival in CDH patients, such as 
APGAR score, SNAP II score, PaCO2 and oxygenation index. However, almost all are based 
on relatively small groups of patients, are difficult to apply or have not been validated 
(9-12). 
Brindle et al, and the Congenital Diaphragmatic Hernia Study Group (CDHSG) have 
developed a simple early clinical prediction rule in a large cohort to identify low (<10%), 
intermediate (~20%), and high risk (~50%) of death in infants. This prediction model is 
based on birth weight, 5-minute Apgar score, severe PH on echocardiography, and the 
presence of cardiac and chromosomal anomalies (13). Validation of the prediction rule 
showed reasonable discrimination among these three groups, but an underestimation of 
mortality in the low risk group (13, 14). 
Maybe the light at the horizon can be seen more clearly when incorporating prenatal and 
postnatal variables in one model. Prenatal variables seem to be able to adequately predict 
lung hypoplasia and the need for ECMO, but the prenatal assessment of O/E LHR or liver 
herniation as a marker for lung vascularization and postnatal PH seems less reliable (15). To 
evaluate the effect of PH on mortality, postnatal variables are still essential for the accurate 
prediction of outcome in these infants. However, it is not easy to develop such a tool. 
Oh et al. made a predictionmodel using polyhydramnion, gestational age at diagnosis, 
O/E LHR, best oxygenation index and tricuspid regurgitation, in a small group from a 
single center(16). They used tricuspid regurgitation on the first day of life as definition 
for PH. Unfortunately the reporting of PH on echocardiography is not standardized 
and different definitions are being used. In Europe, the presence of PH is often defined 
as pulmonary pressures higher than >2/3 of the systemic pressures instead of supra-
systemic pulmonary pressures as often used in other centers (13, 17). Furthermore, the 
timing of the measurement is very different between centers (13, 14). Furthermore, when 
using a voluntary database, or a database based on coded diagnosis, the accuracy of the 
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data is difficult to interpret. More consistent measuring techniques and reporting would 
probably make these different variables more suitable for the use of outcome prediction. 
And last but not least, the treatment of these patients needs to be standardized for the 
accurate prediction of outcome. This will minimize variation in outcome due to treatment 
differences. Right now, the same treatment protocol is being used in most centers in 
Europe, initiated and guided by the CDH-EURO Consortium guidelines (17). Also, more 
recently in Canada, standardized guidelines have been developed (18).
CDH continues to be a birth defect with a high mortality and morbidity.The work of 
Dassios and collagues (3) is a next step in the identification of mortality risk at an early 
time after birth. Although many tools have been developed to predict mortality, none 
of them is perfect. With standardized measurement of prenatal and postnatal variables, 
incorporated in one model, prediction might become more accurate in the future. 
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ABSTRACT
Background: Congenital diaphragmatic hernia (CDH) is a rare congenital anomaly with 
a mortality of approximately 27%. The Congenital Diaphragmatic Hernia Study Group 
(CDHSG) developed a simple postnatal clinical prediction rule to predict mortality in 
newborns with CDH. The aim of the study is to externally validate the CDHSG rule in 
the European population and to improve its prediction of mortality by adding prenatal 
variables. 
Methods: We performed a European multicenter retrospective cohort study and included 
all newborns diagnosed with unilateral CDH, born between 2008 and 2015. Newborns 
born from November 2011 onwards were included for the external validation of the rule 
(n=343). To improve the prediction rule, we included all prenatally diagnosed patients 
born between 2008 and 2015 (n=620) and collected pre- and postnatal variables. We 
build a logistic regression model and performed bootstrap resampling and computed 
calibration plots. 
Results: With our validation dataset the CDHSG rule had an area under the curve (AUC) 
of 79.0% showing a fair predictive performance. For the new prediction rule prenatal 
herniation of the liver was added and absent 5 minute Apgar score was taken out. The 
new prediction rule showed good calibration and with an AUC of 84.6%, it had good 
discriminative abilities. 
Conclusion: In this study, we externally validated the CDHSG rule for the European 
population, which showed fair predictive performance. The modified rule, with prenatal 
liver herniation as an additional variable, appears to further improve the model’s ability to 
predict mortality in a population of patients with prenatally diagnosed CDH.
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INTRODUCTION
Congenital diaphragmatic hernia (CDH) is a severe developmental defect of the diaphragm 
causing lung hypoplasia and pulmonary hypertension (PH), leading to a mortality of 
27% in live-born patients (1). Identification of risk factors that prognosticate outcome 
in patients with CDH is essential to accurately counsel parents and to compare patient 
populations and management strategies. 
Prenatally, outcomes are predicted using observed-to-expected lung-to-head ratio (O/E 
LHR), MRI calculations of lung volumes and position of the liver and stomach (2-7). These 
prenatal parameters can be used to predict lung hypoplasia, but do not seem to reliably 
predict PH (8, 9). 
For the postnatal prediction of survival, there are several prediction models and variables 
such as SNAP II score and oxygenation index. However, many  are based on relatively small 
groups of patients, are difficult to apply or have not been externally validated (10-14). 
Brindle et al, and the Congenital Diaphragmatic Hernia Study Group (CDHSG) have 
developed a simple early clinical prediction rule in a large cohort of patients to identify 
low (<10%), intermediate (~20%), and high risk (~50%) of death in the postnatal period. 
This prediction model is based on birth weight, 5-minute Apgar score, severe PH, and the 
presence of cardiac and chromosomal anomalies (15). Validation of the prediction rule 
showed reasonable discrimination between groups (15, 16). 
This postnatal model has been favorably compared to prenatal predictors (17). However, 
there is potential value in combining post- and prenatal risk factors within a single 
prediction model. Prenatal and postnatal predictors have only been integrated in one 
prediction model in a small group of patients from a single center (18). The aim of our study 
was to externally validate the CDHSG clinical prediction rule in a European population and 
incorporate additional prenatal variables to further improve the rule. 
PATIENTS AND METHODS
The data were collected from four high-volume CDH centers, treating ten or more patients 
with CDH per year (19). These centers are part of the CDH Euro Consortium; Erasmus 
University Medical Center, Rotterdam, Radboudumc Amalia Children’s Hospital, Nijmegen, 
The Netherlands, University Hospital Mannheim, Mannheim, Germany and Bambino Gesu’ 
Children’s Hospital, Rome, Italy. The CDH Euro Consortium is a voluntary collaboration 
of European institutions, that works together in research. This collaborative group also 
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developed the CDH EURO Consortium management guidelines that are implemented in 
all participating centers (1, 20). Institutional review board approval was obtained from the 
Medical Ethics Committee Erasmus MC in Rotterdam (MEC2016-109). 
For the external validation of the CDHSG prediction rule, patients born before November 
2011 were excluded, because  these patients were included in the CDHSG database and 
used for the development of the original CDHSG prediction rule (15). We included all live-
born infants with CDH, born between November 2011 and 2015. We reviewed the data of 
these patients from the local CDHSG database and added missing data from the medical 
files if available. The collected data were in accordance with the definitions used by Brindle 
et al; low birth weight (<1500 gram), low Apgar score <7 at 5 minutes or the absence 
of an Apgar score, severe PH defined as right to left shunt or estimated supra-systemic 
pulmonary pressures on the first echocardiography, chromosomal anomalies, defined as 
any abnormalities in the chromosomal array, and major cardiac anomalies, classified as 
all anomalies other than patent foramen ovale, patent ductus arteriosus, atrial septum 
defect and ventricular septum defect (15). 
The data of each patient were entered in the CDHSG prediction rule to calculate a total 
CDH risk score, ranging from 0 to 8 (table 1). This score was used to stratify the patients 
into one of the 3 risk groups; low (0), intermediate (1-2) and high risk (3-8). 
For the implementation of prenatal variables in the CDHSG prediction rule, we included 
all live-born infants with prenatally diagnosed CDH, born between 2008 and 2015. The 
predictors in the CDHSG prediction rule were reviewed. Most of the variables were used 
as binary variables.  However, to further improve the model, birth weight was also tested 
as a continuous variable and low Apgar score was defined as <5 at 5 minutes or <7 at 
5 minutes. Missing Apgar score was left out, as one of the centers never calculates an 
Apgar score for CDH patients. Also, after discussion with an expert group, consisting of 
pediatric intensivists, neonatologists and prenatal specialists across participating centers, 
we decided that the variable chromosomal anomalies should always be in the model, 
because of its major significance in the decision to start and continue treatment.   
Additionally,  candidate pre- and postnatal predictors were selected by the expert group. 
The first measured O/E LHR after 18 weeks of gestation was included as a continuous 
variable. The presence of intrathoracic liver herniation on the last prenatal ultrasound was 
used as a binary variable. Also, the side of the hernia, fetal endotracheal occlusion (FETO), 
the presence of polyhydramnios (21), gestational age at diagnosis and gestational age at 
birth were selected.   
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STATISTICAL ANALYSES
To describe the baseline characteristics of the  patients with CDH, medians and IQRs were 
used for continuous variables and percentages for categorical variables. Comparisons 
between baseline characteristics and death before discharge were made using the chi-
square test for categorical variables and the Mann-Whitney test for continuous variables. 
Comparisons between centers were made using Kruskal-Wallis and chi-square tests.    
For the external validation of the CDHSG prediction rule, multiple imputation was 
performed for missing data (table 2), creating 100 databases using fully conditional 
specification. Because the available data between centers were heterogeneous, we used 
“center” as a covariate in the multiple imputation. Then, the CDHSG prediction score was 
calculated for each individual using the final prediction rule as used by Brindle et al (15) as 
well as the original equation, which was used to develop the CDHSG prediction rule (table 
1). The predictive performance was assessed using calibration plots and the c-statistic (i.e. 
the area under the receiver-operating-characteristic curve). Also, the predicted outcome 
of the final equation was compared with the observed outcome in the study cohort from 
the pooled database.
For the new model, predictors were tested using univariate analysis, assessing if a variable 
was associated with increased mortality. We corrected for center. The selected variables 
were put into a multivariable logistic regression model using the stepwise backward 
method. In every step the variable with the highest p-value was excluded if its p-value 
was >0.1, and this was repeated until all variables included in the model had p<0.1. The 
model was evaluated with a calibration plot, assessing the discriminatory abilities of the 
model, followed by bootstrapping to correct for the optimism of the model. We then 
calculated the predicted risk per patient and plotted the ROC curves to determine cut-
off values of the predicted risk for 3 risk groups; low, intermediate and high risk. SPSS 
Statistics version 24 and R version 3.6.1 with the packages rms and mice were used for the 
statistical analyses.     
RESULTS
753 patients were diagnosed with CDH between January first, 2008 and December 
31st, 2015. Eight patients were excluded, because there were no patient characteristics 
available. Fourteen pregnancies resulted in an intra-uterine fetal demise. 343 patients were 
born between 2011 and 2015, and their data were used for the validation of the original 
prediction rule. 620 patients were included to develop the new rule. In 111 patients the 
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diagnosis was not prenatally known and therefore they were excluded for the new rule. 
This postnatally diagnosed group had a mortality of 9%.
Table 1 CDHSG prediction rule and the new model
Original CDHSG prediction 
equation 
1/(1 + exp(2.65 
- log(2.634)*(low birth weight)
- log(2.718)*(low 5 min Apgar score <7)
- log(4.678)*(missing 5 minute Apgar score)




Final CDHSG prediction 
rule (15)
Low birth weight (<1500 g)
Low 5 minute Apgar score (<7)













New prediction model 
with additional prenatal 
variable 
1/(1 + exp(-0.6735 
+ 0.0013*(birth weight (g)) 
– 1.7150*(low 5 minute Apgar score <7) 
– 1.4871*(severe PHT)
– 0.9471*(MCA) 
– 0.8754*(chromosomal anomaly) 
– 0.7235*(intrathoracic liver herniation on prenatal US))
%
PHT = pulmonary hypertension; MCA = major cardiac anomalies; US = ultrasound 
Baseline characteristics of both patient groups are shown in table 2. In 70.3% of the 
patients in the cohort used for the validation, the first echocardiogram was performed 
within the first 24 hours of life. The overall mortality was 18%. In the group used for the 
new rule, 76.9% of the patients, had their first echocardiogram performed within the first 
24 hours of life. Their overall mortality was 23%. In both groups, the baseline characteristics 
of the patients that survived were significantly different from those who died, except for 
sex (table 2). Also, these characteristics also differed significantly between centers the, as 
presented in table 3. 
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The outcome of the CDHSG prediction rule after multiple imputations is shown in table 4. 
46% of the patients was grouped in the low-risk group (score 0), with an observed mortality 
of 4%, and 38% was grouped in the intermediate group (score 1-2) with a mortality of 
22%. The high-risk group (score 3-8) was smaller, containing 16% of the patients with a 
mortality of 66%. The discrimination of the model was moderately strong with a c-statistic 
of 0.784 for the original equation and 0.790 for the final CDHSG prediction rule. 


















6.6% 17.1% 24.1% 45.5% 60.1% 87.9% 87.5%
Observed 
mortality
4.0% 18.5% 22.9% 42.7% 63.6% 87.5% 100%
 
 
Subsequently, to develop a new rule, the original prediction rule was modified. First, 
logistic regression was performed within the large dataset using a backwards elimination 
algorithm. Missing data were imputed. O/E LHR, side of the hernia, gestational age at birth, 
FETO, polyhydramnios, Apgar score <5 at 5 minutes, and gestational age at diagnosis were 
excluded from the model with backward elimination. Although chromosomal anomalies 
had a p-value >0.1, we forced it into the model (table 5). 
The new model contains birth weight as a continuous variable, and intrathoracic 
herniation of the liver, major cardiac anomalies, chromosomal anomalies, Apgar score 
<7 at 5 minutes and severe PH as binary variables (table 1).  Evaluation of the model in 
a calibration plot showed good discrimination of the model with a c-statistic of 0.859. 
Correcting for the optimism of the model, estimated around 1.4%, the c-statistic is 0.846. 
Supplement figure 1 shows the ROC curve of the new model. We then stratified the 
patients into one of the 3 groups; low, intermediate and high risk of mortality. When using 
<10% (mild), 10-50% (moderate) and >50% (severe) risk of mortality as cut-off points, the 
cut-off between the mild group and the moderate group showed a sensitivity of 90.8% 
and a specificity of 55.4%, whereas the cut-off between the moderate and the severe 
group showed a sensitivity of 49.3% and a specificity of 93.5%. 
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Table 5 Odds ratios for mortality for variables in the new model
Variable Adjusted OR 95% Confidence interval
Intercept 1.9611 0.5570 – 6.9048
Birth weight (gram) 0.9987 0.9983 – 0.9991
Intrathoracic liver herniation 2.0616 1.2300 – 3.4555
MCA 2.5781 0.9631 – 6.9020
Chromosomal anomalies 2.3998 0.8277 – 6.9579
Severe PHT 4.4242 2.6159 – 7.4826
Apgar score <7 5.5567 3.0719 – 10.0513
OR = odds ratio; MCA = major cardiac anomalies; PHT = pulmonary hypertension
The disease severity using the rules per center is presented in table 1 and 2 of the 
supplement.
DISCUSSION
In this study we externally validated the CDHSG rule in the European population. We found 
the rule had fair discrimination, but also room for optimization, comparable to the internal 
validation of Brindle et al (15). Bent et al also validated the rule in a large group of patients 
with CDH born in California, and found an underestimation of mortality in the patients 
with a score of 1 (16). We did not find this in our population. This might be explained by the 
difference in health care systems in Europe and the United States. In Europe, centralized 
care is more common and many patients with CDH are born in high volume centers. It is 
increasingly recognized that centralized care improves outcome in these patients (19). 
This might also explain the lowest mortality in patients born in the largest center of our 
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study. Furthermore, in Europe many CDH centers collaborate in the CDH Euro Consortium, 
which has developed a standardized treatment protocol, increasing survival from 67% to 
88%  (20, 22). 
Even though it seems valid to use the model, some variables were not useful or difficult 
to apply in our population. In one of the four centers, Apgar scores were never measured 
because the medical team feels it is not a useful tool in this patient group. Patients with 
CDH will have a lower Apgar score as they are intubated directly after birth (20). Brindle 
et al theorized that the absence of an Apgar score implies a sicker infant, but this was 
not applicable to our cohort. Also, the measurement of PH on echocardiography is not 
standardized and different definitions for PH are being used. Brindle et al used right to left 
shunting or estimated supra-systemic pulmonary pressures. In Europe, the presence of PH 
is often defined as pulmonary pressures higher than >2/3 of the systemic pressures (20, 
23, 24). Furthermore, the timing of the measurement differs between centers. Brindle et 
al used the earliest echocardiography in the model, Bent et al used PH at discharge (16). 
Presumably, the incidence of severe PH would be underestimated in Bent’s study, as many 
patients with PH have already died and in others pulmonary pressures have decreased 
(25). The registered incidence of PH in non-survivors is only 33.5% in Bent’s study, while 
it is over 50% in our cohort, and over 60% in the CDHSG population, supporting this 
assumption (15, 16). 
To improve the power of the original prediction rule, combining prenatal and postnatal 
variables is presumably superior. Prenatal variables have been found to adequately 
predict lung hypoplasia and the need for ECMO but are less reliable as a marker for PH (8, 
9). To predict mortality postnatal variables are still essential. Different prenatal variables 
were tested in the model and eventually only the position of the liver was a significant 
variable. Surprisingly, O/E LHR was not of additional value to the model, while in earlier 
studies O/E LHR did have a role in predicting survival. It is a more reliable prenatal 
predictor than the lung-to-head-ratio, as it is a stable variable during pregnancy (6, 26). 
However, different O/E LHR measurement techniques are being used between centers, 
and there is a learning curve in the examination of the O/E LHR (27, 28). In two of the 
centers, the tracing method was always used, while in the others also the longest axis 
diameter method was used. The longest axis diameter method overestimates the O/E LHR 
up to 34% and has a larger inter-observer variability (29-31). In addition, the O/E LHR can 
be calculated with multiple calculators (i.e. www.totaltrial.eu or www.perinatology.com) 
which results in different ratio’s. In our study, the method of calculation varied. Measuring 
lung volumes on MRI holds promise (32). However, in many centers it is not possible to use 
MRI for this purpose, due to costs and lack of availability. For this study, analysis of fetal 
lung volume resulted in too many missing data. Another prenatal predictor is stomach 
position (7). This measure, however, is not implemented in standard prenatal care and 
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could therefore not be analyzed for this study. More consistent measuring techniques and 
reporting would probably make these different prenatal variables more suitable for use in 
outcome prediction.  
For the modified model, we also made some changes to the original variables. “Missing 
Apgar score” was taken out.  On the other hand, we kept chromosomal anomalies in the 
model, although its association with mortality was not significant  (p-value was >0.1). 
Possibly some patients had a clinically insignificant abnormality on array, however, as these 
data are retrospective, it was not possible to reliably select only clinically relevant cases. 
Therefor we choose to include all patients with abnormalities on chromosomal array. CDH 
is associated with numerous chromosomal anomalies, and often the associated anomaly 
has a major  impact on mortality (33, 34). 
The strength of our study is the large population of  patients with CDH and the amount 
of prenatal data available. Often, the implementation of prenatal data in a prediction 
model is difficult due to the amount of missing data (15). Also, when using a voluntary 
database, or a database based on coded diagnosis, the accuracy of the data is difficult to 
interpret. We were able to go back to the original patient files when needed. However, we 
did have some missing data as shown in table 2, which we corrected for using multiple 
imputation, a statistical tool often used in this setting. However, possibly some predictors 
were not significant in the model due to the large amount of missing data, such as 
the presence of polyhydramnios and the gestational age at birth. Furthermore, as all 4 
centers are part of the CDH Euro Consortium, postnatal clinical management is similar in 
all centers, increasing the reliability of an early prediction model, but it also potentially 
limits the generalizability of our study and may contribute to an optimistic assessment 
of model performance. Therefor our new model needs additional external validation 
in a more heterogeneous group like the patients in the CDHSG database, to prove its 
generalizability. Also, as prenatal data are necessary for the new rule, other settings with 
imperfect prenatal care provision may not benefit as much from this new model. The 
original CDHSG model is very easy to apply at the bedside. Although this is not true for 
our model, a more complicated calculation is necessary.
In a population with a rare congenital defect with high mortality and morbidity, it is very 
important to reliably predict outcomes. Prenatally, this can guide parents and clinicians in 
decisions regarding perinatal management, and the referral to high-volume centers for 
the delivery in areas with a low density population. Postnatally, adequate prediction can 
help parents to better understand the course of their child’s illness. In addition, it can also 
be used for standardized reporting and benchmarking between centers. A good postnatal 
prediction model can potentially improve care for specific groups of patients with CDH. 
This model can act as a practical tool when stratifying patients into risk groups, such as 
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mild, moderate and severe. The mild group of patients, identified with a highly sensitive 
threshold, could receive less aggressive treatment, such as a spontaneous breathing trial at 
birth (35). On the other hand, the severe group, identified with a highly specific threshold, 
could potentially benefit most from more aggressive experimental therapies, and the true 
benefit of these therapies could be detected earlier as there would be no dilution of effect 
due to the inclusion of  patients with lower risk. For all these reasons, there is a need for 
a reliable prediction model, that can be applied on the first day of life (36). The power of 
a prediction model is dependent on the availability of the information needed for the 
calculation. Prenatal data are not readily available in some areas in the world.  However, 
the only prenatal parameter significant in our model, the prenatal position of the liver on 
ultrasound, is reasonably easy to evaluate.
CONCLUSION
We have successfully validated the CDHSG prediction rule within a European population. 
We also developed a modification of the original rule, implementing prenatal variables, 
with apparent improvement of the predictability of mortality. Standardization of the 
measurements of prenatal variables such as O/E LHR and the postnatal variable PH, could 
potentially increase their predicting value and further improve these models. Validation 
of this modified rule is needed to evaluate its generalizability.  
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Supplemental digital content figure 1 Receiver operating characteristic curve of the new 
prediction model








Score: 1 - 2 
(intermediate risk)
Score: 3 - 8
(high risk)
Rotterdam 79 20.3% 36.4% 52.0% 11.6%
Nijmegen 59 27.1% 32.2% 44.6% 23.2%
Mannheim 179 13.4% 61.1% 27.5% 11.4%
Rome 26 26.9% 0.0% 56.5% 43.5%
After multiple imputation of missing data for CDHSG prediction rule (n=100 databases), the CDHSG 
prediction rule score was calculated for each patient. Data presented in the table are from the 
pooled database.


















Rotterdam 129 27.9% 17.9% 53.8% 35.7% 10.5%
Nijmegen 62 33.9% 26.9% 31.4% 49.2% 19.3%
Mannheim 336 17.0% 22.1% 48.2% 37.1% 14.7%
Rome 93 30.1% 27.6% 43.6% 33.7% 22.7%
After multiple imputation of missing data for the new prediction rule (n=100 databases), the new 
prediction rule was used to calculate the mortality risk for each patient. Data presented in the table 
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ABSTRACT
Background and objective: International consensus guidelines advice routine 
intubation for all neonates with congenital diaphragmatic hernia (CDH) at birth. However, 
risk of ventilator induced lung injury and the impact on perinatal transition should not 
be underestimated. We introduced a more personalized perinatal management strategy. 
We hypothesized that a spontaneous breathing approach (SBA) in the delivery room is 
justified for newborns with CDH and a low risk of respiratory failure. 
Method: An SBA was prenatally planned in patients born after 35 weeks of gestation 
with an isolated left-sided CDH and an observed-to-expected lung-to-head ratio >50% 
without liver herniation. At birth these patients were respiratory supported as needed, 
with a low threshold for intubation. Between December 2014 and July 2019 16/72 (22%) 
patients received an SBA. We retrospectively evaluated feasibility and safety of an SBA.
Results: The SBA was successful in 7 (44%) patients, 9 (56%) patients were intubated 
due to respiratory failure and needed mild ventilator support with maximum inspiratory 
pressures of median 23cmH2O for a median of 7 days. 1 patient developed pulmonary 
hypertension with need for nitric oxide for 4 days. Survival was 100%. 
Conclusions and Relevance: In this relevant subgroup of infants with CDH and favorable 
prenatal parameters, an SBA is feasible and safe. This personalized perinatal approach 
avoids overtreatment with potential adverse side effects. 
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INTRODUCTION
Congenital diaphragmatic hernia (CDH) is a developmental defect of both the diaphragm 
and the developing lungs, resulting in the herniation of the abdominal organs in the 
chest cavity. Pulmonary hypoplasia and pulmonary hypertension (PH) often result in 
respiratory insufficiency immediately at birth (1). CDH occurs in 1 in every 2500 live births, 
and is associated with an improved survival of approximately 70-80% in live-born patients 
since the implementation of international treatment guidelines (2-4). According to these 
consensus guidelines, the key principle during the perinatal stabilization period is avoiding 
high airway pressures whilst establishing adequate oxygenation and cardiovascular 
stability (2). Consequently, infants are routinely intubated immediately at birth and gentle 
ventilation strategies are adopted to prevent ventilator induced lung injury (VILI) (2, 5-7). 
However, with the improvement of prenatal diagnostics, such as prenatal ultrasound 
and fetal magnetic resonance imaging (MRI), the severity of pulmonary hypoplasia 
can be estimated more precisely (8, 9). This enables composing personalized perinatal 
management strategies. In newborns with left-sided CDH, an observed-to-expected lung-
to-head (O/E LHR) over 50% and an intra-abdominal liver position (mild group) assessed 
by prenatal ultrasound, survival rates exceed 90% (10, 11). For these patients, the current 
guidelines potentially result in overtreatment, and the risk of VILI and the impact on 
perinatal transition should not be underestimated (12). 
We hypothesized that in this group with relative mild disease, a spontaneous breathing 
approach (SBA) is feasible and safe during fetal to neonatal transition. In this paper we 
describe our experience after adjusting our local protocol, allowing a planned SBA. 
STUDY DESIGN AND METHODS 
We performed a retrospective single center study in newborns with CDH, born at 
Erasmus University Medical Center Rotterdam, a national and level 3 referral center 
with extracorporeal membrane oxygenation. This study was approved by the local IRB 
(MEC2019-714) and informed consent was waived due to the retrospective design of the 
study. 
Our local protocol is based on the adjusted CDH EURO Consortium guidelines (2). 
Accordingly we modified our protocol in December 2014, allowing planned SBA in patients 
with mild CDH born >35 weeks of gestation(2). We used the O/E LHR measured between 
24 and 38 weeks gestational age(8). Congenital anomalies were defined as anatomic 
anomalies on prenatal ultrasound or genetic mutations (microarray). We included all 
consecutive patients born between December 2014 and July 2019 who met these criteria. 
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The SBA was classified as failed if the infant required intubation any time before elective 
intubation for surgery. Surgery was planned electively with an experienced CDH operating 
team.
In our perinatal center, a perinatal treatment plan is made for all patients with CDH in a 
multidisciplinary team meeting around 32 weeks of gestation, attended by obstetricians, 
fetal medicine specialists, neonatologists, pediatric intensivists and surgeons. Prior to 
this, both a fetal medicine specialist and a postnatal specialist counsel the parents and 
discuss the treatment strategies, including an SBA if applicable. Postnatal resuscitation is 
executed according to CDH guidelines(2). The newborn is positioned on the resuscitation 
table and a Replogle tube, 10 French, is inserted for continuous stomach decompression. 
In case of planned SBA, the infant is supported with oxygen if necessary (Neopuff™ infant 
T-piece resuscitator, Fisher&Paykel Healthcare Ltd), aiming for preductal saturations 
>85%(2). Continuous positive airway pressure (CPAP) is allowed. The infant is intubated if 
insufflation breaths or ventilation are needed, since positive pressure ventilation via mask 
increases the air in the digestive tract, subsequently compressing the lungs, resulting in 
hypoxia and PH. 
Maximum oxygen need on the ventilator was defined as oxygen need after stabilization 
in the delivery room. During the initial treatment in the delivery room, often 100% oxygen 
is given, and per protocol this is decreased slowly. Therefore we used a cut-off point of 3 
hours after delivery for the highest oxygen need.  
Patient characteristics and outcome parameters were described as either absolute 
numbers or percentages for categorical data, or median (interquartile range; IQR) for 
continuous data. The Mann Whitney U test was used to compare patients in whom SBA 
was successful with patients who required intubation. 
RESULTS
During the study period 71 newborns with CDH were treated in our hospital. Of those, 
18 (25%) patients fulfilled the criteria for an SBA, but in 3 patients this was not prenatally 
planned and therefore not performed (figure1). Patient characteristics of the 16 patients 
that received an SBA are shown in table 1. At a median of 32 weeks and 1 day (IQR 30+4-
34+1), the O/E LHR used in the multidisciplinary team meeting, was  measured. This O/E 
LHR was median 57% (52-74-9).  














Figure 1 Patient flow chart
CDH= congenital diaphragmatic hernia, SBA= spontaneous breathing approach 
SBA was successful in 6 out of 15 patients (40%); 3 required CPAP for several minutes, and 
5 were transferred to the unit with binasal cannulae (Intersurgical), 1-2 liters FiO2 30-40%. 
All were electively intubated for surgery. 9 out of 15 patients required intubation after 
birth: 7 at birth, 2 several hours after birth in the intensive care unit. 8 of these intubated 
patients received relatively mild ventilation with a median peak pressure of 23cmH2O 
(IQR 19.5-25), they were extubated shortly after the surgical procedure with a median of 
3.5 days (IQR 1.5-5). Only one patient (O/E LHR 57%) developed PH and was treated with 
inhaled nitric oxide for 4 days and oxygen supplement therapy for 28 days. Apart from the 
anticipated difference in ventilation days and duration of oxygen therapy, there were no 
clinical differences between patients with successful and failed SBA (table 1). The overall 
survival was 100%.
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Table 1 Patients with and without successful SBA
Successful SBA (n=6)




Male gender 50% 78%
Birth weight (kg) 2.78 (2.38-3.22) 3.0 (2.85-3.20) 0.24
Apgar score 1 minute 7.5 (5.8-8) 6.5 (4.3-7.8) 0.41
Apgar score 5 minutes 8 (8-9.3) 7 (7-8.8) 0.18
Gestational age at birth (weeks) 37.8 (37.0-38.5) 38.3 (37.9-38.6) 0.37
O/E LHR (%) 66 (49.8-82.3) 55 (52-64.5) 0.56
Peak ventilator pressure* 
(cm H2O)
23.5 (21.5-27) 23 (19.5-25) 0.37
VIS score* 0 (0-18.8) 4.6 (0-15.5) 0.57
Days on ventilator 1 (1-2.5) 7 (4-10) <0.05


















Patch repair 2 (33%) 5 (56%) 0.53
Days on ventilator after surgery 1 (1-2.5) 4 (2-5.5) 0.05
Total oxygen therapy (days) 4.5 (2.5-7) 15 (5-17) <0.05
Discharge from ICU in days 6 (5-10.75) 18 (7.5-25) <0.05
Discharge home in days 18 (9-31.5) 28 (13.5-45) 0.44
Medical support at discharge**
None 





Abbreviations: ICU= intensive care unit, O/E LHR= observed-to-expected lung-to-head ratio, SBA= 
spontaneous breathing approach, VIS= vasoactive inotropic support score, IQR= interquartile range
*recorded continuously during ICU admission, **defined as ventilator, oxygen, pharmaceutical, 
G-tube feeding
DISCUSSION 
In this study we showed that, in a selected but relevant (20-25 %) group of newborns with 
CDH, an SBA is feasible and safe. To our knowledge, this is the first study to report a more 
conservative approach in this subset of infants as suggested by Snoek et al and Morini et 
al (2, 13).  This fits in a more personalized approach in the delivery room and improves 
postnatal parent-infant interaction. 
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The lungs of newborns with CDH are known to be hypoplastic, characterized by decreased 
airway branches, fewer alveoli, and excessive muscularization of the arterioles (14, 15). As 
a result, most newborns with CDH are respiratory insufficient directly after birth. Mortality 
and morbidity in patients with CDH is still substantial, but has decreased considerably 
since the introduction of international consensus guidelines (2, 5, 16). In these guidelines 
all patients with CDH are immediately intubated and ventilated after birth. One of 
the keystones of these guidelines is gentle ventilation to prevent lung damage of the 
hypoplastic lung and to decrease the negative impact of positive intrathoracic pressure on 
pulmonary perfusion (2, 5-7). Despite the improvement of care, the prognosis of patients 
with CDH is still highly variable, depending on the amount of lung hypoplasia and the 
presence of PH. Prenatal parameters, such as O/E LHR and liver position, are considered 
useful predictors for the severity of lung hypoplasia and mortality in these patients (11). 
In patients with an O/E LHR of 50% or higher, and an abdominal position of the liver, 
survival is high (11, 17). For this subgroup of patients with mild CDH, intubation and 
mechanical ventilation immediately after birth has potential unnecessary side effects. 
Positive pressure ventilation can cause lung injury due to a combination of barotrauma, 
volutrauma, atelectrauma and hyperoxia (13). 
It has long been recognized that gentle ventilation strategies are essential to prevent 
barotrauma. Already in 1981, Srouji et al showed that the incidence of pneumothorax and 
interstitial emphysema in patients with CDH was highly associated with ventilation (18). 
With gentle ventilation, using lower peak pressures, this has decreased substantially (19). 
However, in preterm infants, the prevention of invasive ventilation altogether, decreases 
the incidence of bronchopulmonary dysplasia (BPD) and mortality substantially (20). 
In addition, the duration of ventilation in these patients is directly associated with BPD 
(21). In patients with CDH the incidence of chronic lung disease (CLD), defined as oxygen 
dependence beyond 28 days of life, is approximately 30% (4). Although the etiology of 
BPD in preterm infants and CLD in children with CDH is different, both patient groups 
have vulnerable lungs, and gentle ventilation has improved outcome considerably (13). 
Hence, we speculated that in infants with mild disease, mechanical ventilation potentially 
inflicts damage in lungs that actually have sufficient capacity for adequate gas-exchange. 
An SBA has the potential to prevent CLD in patients with mild patients. In our cohort only 
one patient developed mild CLD, with oxygen need until day 28, and overall survival 
was 100%. Although these are promising results, our results should be interpreted with 
caution as our cohort consists of a small selected population with a high a-priori chance 
of survival without sequelae.
Lung injury can also occur when the alveoli and bronchioles collapse and reopen with 
every breath as the patient ventilates below the alveolar opening pressure. This has 
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been described in premature infants and is associated with the absence of surfactant 
(22). Although the lungs of patients with CDH are abnormal, there is no surfactant 
deficiency at birth (23). However, insufficient respiration can enhance the development of 
atelectasis. In our cohort, we prevented atelectrauma by intubating the patients as soon 
as their breathing pattern was insufficient. In case of dyspnea, PEEP was given for several 
minutes to guarantee adequate airway opening, and if needed the patient was intubated 
subsequently. 
Oxygen induced lung injury can be caused by hyperoxia, since high alveolar oxygen 
concentrations cause pulmonary edema, and increase inflammatory markers and cell 
necrosis (24). In term infants the use of oxygen in the delivery room has decreased 
remarkably, since the use of FiO2 1.0 during neonatal resuscitation has been associated 
with increased mortality (25). High oxygen concentrations are still often administered in 
patients with CDH, although the target range for preductal SpO2 in the delivery room 
is 80-95% (2). There are no prospective trials in patients with CDH, evaluating oxygen 
management in the delivery room. A small retrospective trial in CDH patients compared 
the use of FiO2 1.0 with the use of FiO2 0.5 at the start of resuscitation and found no 
adverse effects using less oxygen. However, the need to increase the FiO2 was associated 
with an adverse outcome (26). In lambs the use of FiO2 1.0 in initial ventilation reduced 
the vasodilator response to iNO (27). iNO is the therapy of first choice in CDH patients 
with PH, but the use of FiO2 1.0 potentially reduces its effectiveness (2, 28). Therefore, the 
role of oxygen in the resuscitation of newborns with CDH needs to be evaluated. In our 
population, oxygen was administered via the Neopuff or via nasal prongs with FiO2 1.0. 
Although the Neopuff is probably very sufficient in delivering oxygen, actual FiO2 via nasal 
prongs is substantially lower, preventing hyperoxia (29, 30).
Patients with CDH not only have a highly variable degree of lung hypoplasia, but also 
have a higher risk of PH due to abnormal vascularization of the lungs, causing a delayed 
transition from the fetal to the neonatal circulation and an increase in vascular reactivity. 
After birth, lung aeriation is the main trigger to decrease pulmonary vascular resistance 
and subsequently increase pulmonary blood flow (31). Hypoplastic lungs have a low 
compliance and an impaired clearance of liquid resulting in a delay in  lung aeration(31). 
As such, this often results in transient hypoxia and hypotension after birth, only to be 
mitigated by the immediate initiation of respiratory support. Therefore, only patients with 
favorable prenatal parameters, suggesting adequate lung size, are potential candidates 
for an SBA. In these patients an SBA potentially leads to a more physiological fetal to 
neonatal transition. Immediate intubation after birth might trigger PH as this is a stressful 
event, and although it is preferable to adequately sedate the infant prior to intubation, 
this is not always feasible (2). Also, positive intrathoracic pressure has a negative impact 
on pulmonary perfusion, and the need for sedation has an adverse effect on the systemic 
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blood pressure, potentially increasing the right-to-left shunt over the open ductus 
arteriosus and further decreasing pulmonary perfusion. On the other hand, airway 
collapse is known to trigger PH (32). Therefore it is essential to closely monitor respiratory 
function when performing an SBA to recognize early signs of progressive insufficiency. In 
our cohort, only one patient developed PH, for which iNO was given for a limited number 
of days. Other therapeutic strategies in the delivery room, such as physiological based 
cord clamping, might also play an important role in the reduction of pulmonary vascular 
resistance directly after birth (33, 34). A clinical trial to investigate the role of physiological 
cord clamping in newborns with CDH is on its way (NTR7853). 
In this study we selected CDH patients with the most favorable predicted outcome. Both 
right-sided CDH and an intra-thoracic position of the liver decreases survival substantially 
(35, 36). Other associated abnormalities, such as cardiac anomalies and chromosomal 
anomalies, independently influence outcome of patients with CDH negatively, and were 
therefore also excluded from the SBA (37). However, in more than half of our patients 
the SBA was not successful, even though prenatal parameters were equal in both the 
successful and the unsuccessful group. Also, one patient developed PH even though the 
prenatal parameters were reassuring. Although the prenatal prediction of lung hypoplasia 
seems reliable, the prediction of PH is not (38). In our study we used the tracing method 
to calculate the O/E LHR on prenatal ultrasound for prediction of pulmonary hypoplasia. 
This is the most reliable measurement technique of O/E LHR with a relatively low inter-
observer-variability (39, 40). Possibly, the use of total fetal lung volume measurement on 
MRI can increase the accuracy of predicting lung hypoplasia and PH (41). However, in our 
setting, no MRI images were made. Although we could not reliably predict the success of 
an SBA, its failure did not seem to negatively affect the outcome in our cohort, since only 
one of the patients developed mild CLD and none died. However, a larger prospective 
trial is needed to validate these results. We believe it is essential for a multidisciplinary 
team to prenatally plan the delivery and for the delivery to take place in an experienced 
center. Close monitoring of the newborn, evaluating the respiratory effort and supporting 
breathing invasively when necessary, are essential. In 3 patients, no SBA was planned and 
therefore it was not performed in the delivery room. Although the reason for this was not 
reported, we hypothesize that this was due to the recent change of the protocol in 2015.
CONCLUSION
In a selected subgroup of patients with CDH and favorable prenatal parameters, a planned 
SBA is feasible and fits in a more personalized approach in the delivery room. In the 
setting of an experienced multidisciplinary team, an SBA safe and avoids overtreatment 
with potential adverse side effects.
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ABSTRACT
Purpose: We developed a pharmacokinetic model of intravenous sildenafil in newborns 
with congenital diaphragmatic hernia (CDH) to achieve a target plasma concentration of 
over 50 µg/l. 
Methods: 23 CDH newborns with pulmonary hypertension (64 blood samples) received 
intravenous sildenafil. Patients received a loading dose of 0.35mg/kg (IQR 0.16mg/kg) 
for 3hours, followed by a continuous infusion of 1.5mg/kg/day (IQR 0.1mg/kg/day). For 
model development Non Linear Mixed Modelling was used. Inter-individual variability 
(IIV) and inter-occasion variability were tested. Demographic and laboratory parameters 
were evaluated as covariates. Normalized prediction distribution errors (NPDE) and Visual 
Predictive Check (VPC) were used for model validation. 
Results: A two-compartment disposition model of sildenafil and a one-compartment 
disposition model of desmethylsildenafil (DMS) was observed with IIV in sildenafil 
and DMS clearance, and volume of distribution of sildenafil. NPDE and VPC revealed 
adequate predictability. Only postnatal age increased sildenafil clearance. This was partly 
compensated by a higher DMS concentration, which also has a therapeutic effect. In this 
small group of patients sildenafil was tolerated well. 
Conclusions: This model for sildenafil in CDH patients shows that concentration targeted 
sildenafil dosing of 0.4mg/kg in 3 hours, followed by 1.6mg/kg/day continuous infusion 
achieves appropriate sildenafil plasma levels. 
PK modeling of sildenafil in newborns with CDH    |   89 
6
INTRODUCTION
Congenital diaphragmatic hernia (CDH) is a developmental defect of the diaphragm with 
abnormal lung development and pulmonary vasculature growth, resulting in pulmonary 
hypertension (PH) (1). CDH is associated with a reported mortality of approximately 27% 
in live-born patients since the implementation of international treatment guidelines (2-4). 
PH is one of the most important risk factors for poor outcome in infants with CDH (1, 5, 6). 
During fetal life, high resistance in the pulmonary circulation is normal and causes most 
of the blood flow to bypass the lungs through the ductus arteriosus. As part of normal 
transition, the pulmonary vascular resistance drops immediately after birth, and the blood 
flow through the lung vasculature  increases significantly. Normal values of pulmonary 
vascular pressures, similar to healthy adults, are usually reached around the age of 
two months (7). In infants with CDH, the pulmonary vascular resistance often does not 
drop adequately, due to increased vascular reactivity, excessive muscularization of the 
pulmonary arterioles and increased thickness of the arterial media and adventitia (8). 
Intravenous sildenafil, a phosphodiesterase 5 (PDE5) inhibitor that increases 
cyclic guanosine monophosphate (cGMP) resulting in pulmonary vasodilation, is 
increasingly used in infants with CDH, with promising results (9-11). In newborns with 
persistent pulmonary hypertension of the newborn (PPHN) without CDH, sildenafil 
improves oxygenation index (OI) and survival (12). However, data on optimal dosing, 
pharmacokinetics (PK) and dynamics are scarce in newborns, and CDH patients are often 
excluded from trials. PK of intravenous sildenafil in term neonates with PPHN, using a 
two-compartment model, shows a threefold increase in sildenafil clearance and its active 
metabolite, desmethylsildenafil (DMS) in the first week of life (13). DMS has a 50% potency 
compared to sildenafil (14). Volume of distribution was fourfold higher than in adults, 
resulting in a longer half-life (13). 
Also, long term safety data are scarce (15). In a study evaluating safety using a dose-
escalating strategy, intravenous sildenafil was well tolerated and it improved oxygenation 
when using a higher infusion dose. With a 3 hours loading dose of 0.4mg/kg and a 
continuous infusion of 1.6mg/kg/day, target plasma concentration was achieved without 
causing hypotension (16). 
As PH is a major determent of survival in patients with CDH, data on the PK and 
pharmacodynamics of sildenafil are urgently needed. The objective of this study was to 
develop a PK model and dosing regimen for sildenafil in CDH patients.
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METHODS    
Study design
This open label study was conducted in two level 3 referral centers for CDH in Germany 
and the Netherlands between November 2013 and September 2015. Local ethical review 
boards approved the protocol. Twenty-three newborns with CDH and clinical signs of 
PH were treated with intravenous sildenafil. Patients received a loading dose of 0.35mg/
kg (IQR 0.16mg/kg) for 3 hours, followed by a continuous infusion of 1.5mg/kg/day (IQR 
0.1mg/kg/day). However, many different regimens were being used; ten patients received 
a loading dose of 0.4mg/kg in 3 hours, followed by continuous infusion of 1.6mg/kg/day, 
in one patient the infusion was very slowly increased over time, starting with 0.2mg/kg/
day, in others no loading dose was given and a continuous infusion was started, ranging 
from 1.4mg/kg/day to 4mg/kg/day. Target plasma sildenafil levels over 50 µg/l were aimed 
for, assuming that the same target range is applicable in CDH patients compared to other 
causes of neonatal PH (16). DMS was not added to calculate this target range, because the 
target range for DMS is unknown and DMS was also not taken into account in the study of 
Steinhorn et al (16). The patients were treated as per protocol according to international 
consensus (3). Patient and baseline characteristics of the 23 patients are provided in the 
supplemental table 1. All patients received inotropic drug support and were treated with 
inhaled nitric oxide (iNO). One patient started treatment with bosentan in the second 
week of life. Thirteen patients needed extracorporeal membrane oxygenation (ECMO) 
(median time of start 8:15h after birth, IQR 9:39h), of whom two were already on ECMO 
before sildenafil initiation, overall mortality was 26%. 
Primary outcomes were the PK of sildenafil and its active metabolite, DMS. Safety data 
were collected as secondary outcome variables. Oxygenation Index (OI) was used to 
evaluate the clinical effect of sildenafil on PH. Hypotension was defined as mean blood 
pressure lower then gestational age in weeks. The Vasoactive Inotropic Score (VIS) was 
used to evaluate cardiovascular tolerance. This is a scoring system used for the amount of 
inotropic support needed and is negatively associated with long term outcome (17). OI 
and VIS were analyzed using linear regression analysis. 
Laboratory analysis
We used 50 µl EDTA blood and 200 µl internal standard solution (vardenafil in methanol) 
was added. This solution was vortexed for 10 seconds and centrifuged for 5 minutes. 200 
µl supernatant was added to the insert vial, which was used in the Thermo TQS Vantage 
LC-MS/MS. Column 2.1x100 mm Waters Acquity CSH C18 1.7um. The mobile phase A 
consisted of 2mM ammonium acetate in 0.1% formic acid in water. The mobile phase B 
consisted of 2mM ammonium acetate in 0.1% formic acid in LC-MS methanol. Flow rate 
was 0.5ml/min. The mobile phase composition changed linearly during analysis in a 
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percentage mobile phase A (from 80% to 0) and B (from 2% to 100%). Total analysis time 
was 4 minutes. The injected volume was 10µl. The method was validated according to FDA 
guidelines between 2-1000 µg/l for sildenafil and 2-500 µg/l for DMS (18). 
Population PK modelling
PK analysis was conducted with non-linear mixed effects modelling using NONMEM® 
version 7.2 (ICON Development Solutions, Ellicott City, MD) and PsN® (version 3.7.6). 
Pirana software was used as an interface between NONMEM, R (version 3.2.2) and Xpose 
(version 4). Using NONMEM we could estimate average PK parameters for the population 
as well as Inter individual variability (IIV), inter occasion variability (IOV), and residual error. 
Base model development
One- two- and three-compartment models were tested for sildenafil and DSM, using the 
first-order conditional estimation method with interaction (FOCE+I). First a structural 
model for sildenafil  was developed. IIV and IOV, with occasion defined per day, were 
assessed on each parameter using an exponential model. Residual variability was first 
tested with an additive and proportional error for each component. The parameters for the 
base model for sildenafil were fixed when the model for the metabolite was developed. In 
the combined model we estimated all parameters.  
Model selection was based on minimum objective function values, parameter precision, 
error estimates, shrinkage values and visual inspection of the goodness of fit plots. 
Shrinkage was calculated for all model parameters. A shrinkage value below 20% was 
considered acceptable (19).
Covariate model development
Demographic and laboratory characteristics including postnatal age, gender, creatinine, 
urea, aspartate transaminase (ASAT) and alanine transaminase (ALAT), were evaluated 
as potential model covariates. Allometric scaling was used to account for variability in 
PK parameters owing to differences in bodyweight (20). Covariates that significantly 
improved the model in univariate analysis, defined as p≤0.05, were added to the full model. 
A backward elimination process was subsequently performed with statistical significance 
indicated by p≤0.001. Continuous covariates were normalised to the population median 
values and incorporated as power model functions (Eq.1). Categorical covariates were 
transformed to binary covariates and incorporated as shown in Eq.2. 
      (1) 
                (2)          
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With θi being the individual model predicted PK parameter (e.g. clearance) for an individual 
with covariate value covi, θpop being the population estimate for that parameter, covm 
representing the median covariate value and θcov the covariate effect. In the equation for 
categorical covariates covi is either 1 or 0.
Model evaluation
We used multiple procedures to assess the robustness of the parameter estimates and 
to validate the final model. First of all, a bootstrap resampling method was applied (21). 
Thousand bootstrap datasets were generated by sampling randomly from the original 
dataset with replacement. The validity of the model was evaluated by comparing the 
median values and their corresponding 95% confidence intervals of the bootstrap 
replicates with the estimates of the original dataset.  
Subsequently, the model was validated using both visual predictive check (VPC) by 
simulating 500 datasets, and a normalized prediction distribution errors (NPDE) analysis 
(22, 23). The VPCs were prediction corrected and stratified for the covariates that are 
included in the final model. NPDE is a simulation-based diagnostic which can be used 
to evaluate models developed on datasets with variable dosing regimens. The analytical 
value of this method has been previously described by Comets et al (23). 
Concentration effect relationship
Drug concentrations were simulated on the time points of blood pressure measurement to 
find a relationship between the concentration of sildenafil, DMS and hypotension (mean 
blood pressure lower than gestational age), assuming a 50% activity of DMS compared 
with sildenafil. The relationship was tested using Mann-Whitney statistical testing.
RESULTS
Sixty-four samples were taken at different time points between 1 and 385 hours after the 
start of the infusion, 34 of these samples were taken during ECMO. None of the patients 
received hemofiltration. Median sildenafil level of all patients was 200 (range 42-262) µg/l 
at 3 hours and increased to 366 (19-506) µg/l at 12 hours. Infants receiving a loading dose 
of 0.4mg/kg in 3 hours achieved sildenafil levels ranging between 190 and 262µg/l at 3 
hours and between 346 and 506µg/l after 12 hours. Median DMS level within the first 12 
hours was 20 (range 9-85) µg/l with a slow increase to a median of 65 (range 17-92) µg/l 
between 24 and 48 hours. 
To evaluate the effect of sildenafil on OI and VIS, numbers were too small. However, in 
only one patient sildenafil infusion was temporarily stopped after one hour, due to 
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hypotension that could not be sufficiently treated with inotropes. One patient had two 
episodes of hypotension, after 7 hours and 7 days, for which the sildenafil was decreased 
for the same reason. This patient also developed pulmonary haemorrhage after 6 days of 
sildenafil infusion. In both patients, no correlation with high sildenafil levels was seen. No 
other adverse events were seen. 
Base model and covariate analysis
The model included two-compartment disposition of sildenafil and one-compartment 
disposition of DMS with IIV in both clearance of sildenafil and DMS, and in volume of 
distribution of sildenafil. The residual error was described with a proportional error model. 
Allometric scaling with fixed exponents (0.75 CL and Q and 1 for Vd) improved the model. 
Estimation of the exponent did not result in further improvement. 
The base two-compartment model with allometric scaling was used as reference for the 
covariate analysis. After graphical analysis, the univariate analysis resulted in the following 
covariates: ECMO, postnatal age, urea, ALAT and weight. With a median age of 2.4 days, 
postnatal age was the only significant covariate after backward elimination. Increase in 
age resulted in increased sildenafil clearance, as can be seen in Figure 1. Age is presented 
in 3 groups: 2, 6 and 10 days. When age increases, the clearance highly increases. If age is 
increased from 2.4 to 10 days, clearance is increased with a factor of 4 (Table 1). Shrinkage 
(residual error in the model) is good with regards to clearance. Shrinkage is high for 
distribution volume, resulting in a large residual error. 
Figure 1: Simulation of the current dose in which 0,4 mg/kg was given in 3 hours, followed 
by 1.6 mg/kg/day. This leads to concentrations within the therapeutic range. However, in 
the group with the youngest age (2 days) the concentration is in higher target range. The 
therapeutic range of 50-300 ug/l is marked in yellow. 
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Table 1: Parameter estimates of the base model, final model and bootstrap analysis
Base model Final model (rse I %) Bootstrap results 
Median [95% CI]
OFV 1191 1160 1154 [918-1372]
CL sildenafil (L/h) 6.7 5.2 (19) 5.1 [3.7-7.0]
                      Age*(days) 0.58 (26) 0.58 [0.3-0.9]
V1 sildenafil (L) 75.1 115 (30) 118 [61-159]
V2 sildenafil (L) 10 10 (na) NA
Q sildenafil (L/h) 44.3 221 (3) 330 [1.9-13719]
Cl metabolite (L/h) 24.2 25.9 (12) 26.6 [21.2-32.6]
V3 metabolite 1040 366(83%) 287 [79-999]
IIV (%)
Cl sildenafil 50.3 51.3 (24%) 24 [5-65]
V1 sildenafil 32.2 21.0 (55%) 5 [0-35]
Cl metabolite 37.8 40.5 (25%) 15 [2-51]
Residual variability
Proportional Cl sildenafil 0.60 0.50(10) 0.5 [0.4-0.6]
Proportional metabolite 0.57 0.44 (10) 0.4 [0.4-0.5]
*Cl=Cl(sildenafil)*(weight in kg/70)**0.75*EXP(IIV sildenafil)*(AGE/2.4)**0.58, Shrinkage: Base 
model Cl sildenafil 12%, Cl metabolite 26%, V1 61%; Final model Cl sildenafil 11%, V1  59 % and Cl 
metabolite 19%
Evaluation of the final model 
All estimates were within the limits, given the criteria as defined. Goodness-of-fit plots of 
the final model showed that the population predictions and individual predictions were 
evenly distributed around the line of unity when compared with observed concentrations, 
and the conditional weighted residuals were normally distributed over time (figure 
2).  A bootstrap analysis with 1000 bootstrap replicates was performed to obtain 95% 
confidence intervals for all PK parameters. 
Owing to minimization and boundary errors, the bootstrap results were recomputed 
without filtering the samples (1000 runs computed: 495 runs successful). Results of the 
bootstrap are shown in table 1. 
In the VPC a large variation was present. However, the median and the variability were 
within the corresponding simulations (figure 3). This demonstrates the good predictive 
performance of the final model in the internal validation. Evaluation of the predictive 
performance with NPDE analysis showed adequate predictive ability, with distribution of 
the NPDEs not significantly deviating from a normal distribution (figure 4 in supplement).
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Concentration effect relationship
To investigate the relationship between blood pressure and drug concentration, 
simulations of drug concentrations were performed on the time points of blood pressure 
measurement. No correlation was seen. 
Figure 2: Goodness-of-fit plots of the final model. a) Observed concentration (DV) plotted 
against predicted concentration (PRED). b) DV plotted against individual predicted 
concentration (IPRED). C) Conditional weighted residuals versus time after start. D) 
Conditional weighted residuals versus age. 
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Figure 3: Visual Predictive Check of sildenafil (CMT/compartment 1) and DMS (CMT/
compartment 3), showing how well the average trend of the observations (solid line) and how 
well the variability of the observed data (two dashed lines) fall within the model-simulated 
average trend (red shaded area) and the model-simulated variability (blue shaded areas) 
represented as a 95% confidence interval (CI). The average and the variability of the observed 
data both fall within the corresponding simulations.  
DISCUSSION
Although intravenous sildenafil is increasingly used in CDH patients, a structured analysis 
of PK data was lacking. Therefore, the objective of the study was to develop a PK model 
and dosing regimen for intravenous sildenafil in newborns with CDH. A loading dose of 
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0.4mg/kg in 3 hours followed by continuous infusion of 1.6mg/kg/day achieve target 
sildenafil plasma levels within 3 hours. 
Only 5 RCTs with a total of 166 patients, have evaluated the effect of sildenafil in 
newborns, all excluding patients with congenital anomalies, including CDH. When 
sildenafil was compared with placebo or MgSO4, a decrease in OI and mortality was 
seen. When sildenafil was added to inhaled NO there was no difference in outcome 
(24-28). In CDH patients only retrospective data are available. A decrease in pulmonary 
vascular resistance index and an increase in cardiac output were found in a small group 
of oral sildenafil-treated infants with CDH refractory to iNO (9). However, there is a large 
interpatient variability in pharmacokinetics of oral sildenafil (29). Intravenous sildenafil in 
CDH patients was associated with improved OI and the reversal of the right-to-left shunt 
ratio over the ductus arteriosus. However, a significant increase in vasopressor support 
was also observed (10, 30). 
We found that postnatal age increases sildenafil clearance suggesting maturation of 
the expression of hepatic CYP enzymes involved, as also observed by Mukherjee et al. 
Sildenafil metabolism is mostly mediated by two enzymes; CYP3A4 and CYP2C9 (31). The 
activity of both enzymes is very low at birth and increases substantially during the first 
weeks of life (32-34). Also, the improvement of the clinical condition possibly increases 
the metabolic activity of the liver (32, 35, 36). The increase in clearance shows a non-linear 
increase over time and is stronger in younger age as commonly seen in infants (13, 35). 
This increase in clearance lowers sildenafil plasma levels which is partly  compensated 
with the  increase of DMS concentrations in time (figure 1 and figure 5 in supplement). 
A loading dose of 0.4mg/kg in 3 hours followed by continuous infusion achieved target 
sildenafil plasma levels within 3 hours (figure 1). This dosing regime was first described by 
Steinhorn et al. in a dose-escalating trial in newborns with PPHN in the absence of CDH. 
Is this small group of 4 patients, sildenafil plasma levels reached 107.78µg/l at 3 hours 
and 246.28µg/l at 24 hours, and it was well tolerated and improved the OI (16). Our data 
suggest that there is no major difference in the PK of sildenafil in CDH patients, although 
our patients reached therapeutic plasma levels earlier, after approximately one hour. As 
the clinical condition of CDH patients can deteriorate quickly, the ideal dosing regimen 
reaches therapeutic plasma levels as soon as possible with the least possible side effects. 
This seems feasible with the dosing regimen we propose. Evaluation of the clinical effects 
of sildenafil and DMS in CDH patients suggested relative cardiovascular tolerance but a 
more clear effect could not be seen. With the amount of patients and samples, we could 
develop a PK model, however, for the secondary outcome parameter numbers were too 
low. Also, 57% of patients needed ECMO treatment, at that point making the OI invalid to 
analyse the effect of sildenafil on PH. As these are retrospective data, echocardiography 
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was not performed at predefined time points, making it impossible to evaluate the effect 
of sildenafil on PH in these patients. However, in this selected group of critically ill CDH 
patients with PH mortality was 26%, whereas reported overall mortality for CDH patients 
is 27%.  
There are some limitations of the study. As CDH is a rare disease, 23 patients is a relatively 
large group, but to test the model and to better achieve patient targeted dosing, 
prospective external validation is needed. A multicenter RCT, the CoDiNOS trial, has 
started in Europe, comparing iNO with intravenous sildenafil as first line treatment of PH 
in CDH patients (NTR6982). In this trial sildenafil and DMS plasma levels will be collected 
to externally validate the model. 
We were not able to retain a significant effect of ECMO on our model. However, considering 
the increase in circulating volume and the use of an oxygenator one would assume ECMO 
to be of substantial influence(37, 38). We probably did not find this due to the relatively 
few samples taken in only 23 patients. We observed both lowered sildenafil levels as well 
as increased levels when on ECMO.  Ahsman et al evaluated the PK of oral sildenafil in 
infants on ECMO and post-ECMO, and also found contradicting results on the influence 
of ECMO (29, 39). In comparison to the work of Ahsman, new ECMO systems are used 
with smaller tubes and filters. We expect that the effect of ECMO can be better evaluated 
as part of the external validation performed in the CoDiNOS trial (NTR6982). Bosentan is 
known to decrease sildenafil plasma concentrations, but it was not a significant covariate 
in our study, because only one patient was co-treated with bosentan (40). Sildenafil 
loading dose and continuous infusion seems to be tolerated well as in only two patients 
sildenafil had to be temporarily decreased or interrupted due to hypotension. However, 
because of the retrospective character of the study, further analysis of the cardiovascular 
tolerance of sildenafil in this patient group, using VIS, was not possible. Kipfmueller et 
al found an acute improvement of OI but also the need to increase inotropic support in 
patients with CDH (30). In a prospective setting these secondary outcome parameters can 
be evaluated much more reliable.
This is the first study on the PK of intravenous sildenafil in a representative population of 
CDH patients in need for PH treatment. Using population PK modelling, a sildenafil plasma 
concentration model was developed with sparse sampling. In conclusion, intravenous 
sildenafil loading dose of 0.4mg/kg for 3 hours followed by continuous infusion of 1.6mg/
kg/day achieves adequate sildenafil plasma levels. Only postnatal age influences its 
clearance. This dosing regimen was well tolerated in this small group of CDH patients. The 
current PK model is the first step towards concentration targeted sildenafil dosing in CDH 
patients. The model will be further validated in the CoDiNOS trial (NTR6982). 
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Supplemental digital content table 1 Patient characteristics and baseline characteristics (t=0)
Median IQR %
Gestational age (weeks) 37.5 1.7
Weight (kg) 2.95 0.8
O/E LHR (%) 37 17
Liver 
Up 61% (14) 
Down 35% (8) 






Associated anomalies 13% (3)
Surgical repair
Primary closure 30% (7)
Patch 61%(14)
No repair 9% (2)
SNAP score 27 24




ECMO at start sildenafil 9% (2)
Urea (mmol/l) 2.5 0.8
Creatinine (umol/l) 53 10
ASAT (U/l) 38 16
ALAT (U/l) 12.5 8
ECMO during admission 57% (13)
Total days on oxygen 20.6 21.4
Death 26% (6)
O/E LHR = observed to expected lung to head ratio; FETO = fetal endotracheal occlusion; SNAP score 
= score for neonatal acute physiology; VIS = vasoactive inotropic score; OI = oxygenation index; 
ECMO = extracorporeal membrane oxygenation 
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Supplemental digital content figure 4: The graphs in the top row, QQ plots and histogram, 
show the normality of the NPDEs distribution. The graphs in the bottom row, scatter plots 
vs. concentration predictions, show the distribution of the variance. V2 = Time (hours), V3 = 
Predicted concentrations (ug/L)
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Supplemental digital content figure 5: Simulation of a loading dose of 0,2 mg/kg in 2 hours 
followed by individualized dose 0,2 mg/kg/day in the youngest children (2 days), 0,4 mg/kg/
day in the middle category (6 days) and 0,6 mg/kg/days in the group of 10 days. With these 
regimen a lower therapeutic level was anticipated. The therapeutic range is marked in yellow, 
only 50-150ug/l is shown to make the figure more clear.
Supplemental digital content figure 6: ETA clearance versus age in days. There is no trend 
visible as all points are nicely distributed over the graph. 
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ABSTRACT
Introduction: Congenital diaphragmatic hernia (CDH) is a developmental defect 
of the diaphragm that impairs normal lung development, causing pulmonary 
hypertension (PH). PH in CDH newborns is the main determinant for morbidity and 
mortality. Different therapies are still mainly based on “trial and error”. Inhaled 
nitric oxide (iNO) is often the drug of first choice. However, iNO does not seem 
to improve mortality. Intravenous (iv) sildenafil has reduced mortality in newborns 
with PH without CDH, but prospective data in CDH patients are lacking. 
Methods and analysis: In an open label, multicenter, international randomized controlled 
trial in Europe, Canada and Australia, 330 newborns with CDH and PH are recruited over 
a four-year period (2018-2022). Patients are randomized for iv sildenafil or iNO. Sildenafil 
is given in a loading dose of 0.4 mg/kg in 3 hours; followed by continuous infusion of 1.6 
mg/kg/day, iNO is dosed at 20 ppm. 
Primary outcome is absence of PH on day 14 without pulmonary vasodilator therapy and/
or absence of death within the first 28 days of life. Secondary outcome measures include 
clinical and echocardiographic markers of PH in the first year of life. 
We hypothesize that sildenafil gives a 25% reduction in the primary outcome from 68% 
to 48% on day 14, for which a sample size of 330 patients is needed. An intention-to-treat 
analysis will be performed. A p-value (two-sided) < 0.05 is considered significant in all 
analyses. 
Ethics and dissemination: Ethics approval has been granted by the ethics committee 
in Rotterdam (MEC-2017-324) and the central Committee on Research Involving Human 
Subjects (NL60229.078.17) in the Netherlands. The principles of the Declaration of 
Helsinki, the Medical Research Involving Human Subjects Act, and the national rules and 
regulations on personal data protection will be used. Parental informed consent will be 
obtained. 
Registration: Trial registration number NTR6982 (Trial NL6796).
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INTRODUCTION
Congenital diaphragmatic hernia (CDH) is a severe developmental defect of the diaphragm 
with an incidence of approximately 1 in 3000 live births and a mortality of 27% (1). Because 
of this defect, the abdominal organs herniate into the chest causing pulmonary hypoplasia 
and abnormal pulmonary vasculature growth, resulting in pulmonary hypertension (PH) 
(2).  In adults and children, PH is defined as mean pulmonary artery pressure (mPAP) 
exceeding 25 mmHg with a pulmonary capillary wedge pressure of minimal 15 mmHg (3). 
The normal pulmonary vascular transition of the neonate takes around two months 
to achieve these low values of mPAP. During fetal life, there is high resistance in the 
pulmonary circulation which results in most of the blood flow to bypass the lungs through 
the ductus arteriosus and oval foramen. Immediately after birth, the pulmonary vascular 
resistance drops and the blood flow to the lungs significantly increases (4). In contrast, the 
pulmonary vascular resistance often does not drop adequately in children with CDH due 
to a decreased vascular bed associated with lung hypoplasia, and an altered development 
of the pulmonary vasculature with excessive muscularization of the arterioles, with 
increased thickness of the arterial media and adventitia. Although the presence of lung 
hypoplasia can be predicted with prenatal parameters, reliable predictors for PH in 
CDH patients are lacking (5). The incidence of PH in CDH patients is 68-79% and causes 
considerable morbidity and mortality  (1, 2, 6). Therapy in newborns with PH , such as 
inhaled nitric oxide (iNO) and sildenafil, has improved outcomes in general. However, 
trials in infants with CDH are sparse. 
Inhaled nitric oxide (iNO) diffuses rapidly across the alveolar-capillary membrane into the 
smooth muscle of pulmonary vessels to activate soluble guanylate cyclase. This enzyme 
mediates many of the biological effects of iNO, and is responsible for the conversion of 
guanosine triphosphate (GTP) to cyclic guanosine monophosphate (cGMP). The increase 
of intracellular cGMP relaxes smooth muscles via several mechanisms. iNO also causes 
bronchodilation and has anti-inflammatory and anti-proliferative effects (7). In term 
and near term infants with persistent pulmonary hypertension of the newborn (PPHN), 
iNO decreases the median duration of mechanical ventilation and reduces the need for 
extracorporeal membrane oxygenation (ECMO). However, in the two available randomized 
controlled trials (RCT) with a small number of patients with CDH, mortality did not improve 
and more ECMO treatment was needed despite short-term improved of oxygenation in 
some treated patients (8, 9). In the centers of the CDH EURO Consortium, iNO is standard 
of care in infants with CDH and PH although the positive pharmacodynamic effects in 
these infants are less convincing then in infants with PPHN (6, 10). The pathophysiological 
mechanism of this difference is not understood. In resource poor settings iNO is often 
110   |   Chapter 7
unavailable. In the search to find another treatment option, trials to evaluate the effect of 
sildenafil in newborns with PPHN have been conducted (11). 
Sildenafil is a selective phosphodiesterase type 5 (PDE5) inhibitor. PDE5 is an enzyme that 
specifically degrades cGMP. Sildenafil inhibits PDE5, increasing cGMP and NO-mediated 
vasodilatation of the smooth muscles in arteries. Only five RCTs have been performed 
in newborns, all non-CDH patients with PPHN. Four of these studies showed a decrease 
in oxygenation index (OI) and mortality in a setting where iNO was not available, while 
one trial showed no additional benefit of sildenafil when added to iNO (11). Although 
sildenafil is increasingly used in CDH patients, only retrospective data are available (12). A 
decrease in pulmonary vascular resistance index and an increase in cardiac output were 
found in a small group of oral sildenafil-treated infants with CDH refractory to iNO (13). 
Intravenous sildenafil improved OI and reversed the right-to-left shunt ratio over the 
PDA, but it also increased the need for inotropic support (14, 15). However, its effect on 
outcome is unknown. 
We hypothesize that intravenous sildenafil is superior to iNO. iNO is the therapy of first 
choice in most centers despite the lack of evidence, and sildenafil is the most promising 
drug for the treatment of PH in CDH patients and is increasingly being used (6, 12, 16). 
However, no studies have been performed comparing iNO with intravenous sildenafil 
in newborns with CDH and PH or PH alone. Based on the current knowledge, there is 
equipoise for both treatment modalities. 
METHODS AND ANALYSIS
Design
The CoDiNOS (Congenital Diaphragmatic hernia Nitric Oxide versus Sildenafil) trial is a 
prospective, multicenter, international randomized controlled trial conducted in high 
volume pediatric surgical centers in Europe, Canada and Australia. The members of the 
CDH Euro Consortium participating in the trial are listed in the Appendix. 
Objectives 
The primary objective of the study is to determine whether the incidence of PH is lower 
in CDH patients treated with intravenous sildenafil than in patients treated with iNO, 
with the primary outcome defined as the absence of PH on echocardiography on day 
14 without pulmonary vasodilator therapy and without treatment failure and/or death 
within the first 28 days after birth. PH is defined as systolic pulmonary arterial pressure> 
2/3 systolic systemic pressure and/or right ventricular (RV) dilatation/septal displacement 
and RV dysfunction +/- left ventricular dysfunction.
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The secondary outcomes are:
(1) change in OI after 12 and 24 hours of therapy
(2) overall mortality 
(3) the incidence of treatment failure which is defined as: 
 •	 inability to maintain preductal saturations above 85% (± 7 kPa or 52 mmHg) or 
  postductal saturations above 70% (±5.3 kPa or 40 mmHg) 
 •	 and/or increase in CO2 > 70 mmHg (9.3 kPa) despite optimization of ventilator 
  management  
 •	 and/or inadequate oxygen delivery with metabolic acidosis defined as lactate 
  ≥ 5 mmol/l and pH < 7.15 and/or hypotension resistant to fluid therapy and 
  adequate inotropic support  resulting in a urine output < 0.5 ml/kg/hour 
 •	 and/or lactate ≥ 5 mmol/l and pH < 7.15 
 •	 and/or OI consistently ≥ 40 
(4) time on intervention drug,  defined as intervention drug free days after initiation of the 
intervention, calculated on day 14
(5) need for ECMO 
(6) ventilator free days on day 28
(7) the use of drugs for PH treatment during the hospital admission 
(8) the use of pulmonary and/or cardiac medication at discharge and its total duration of 
administration 
(9) short-term and long-term PH on echocardiography at 24 hours, 28 days/discharge and 
6 and 12 months 
(10) the incidence of chronic lung disease
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(11) the development of neurological abnormalities evaluated with ultrasound of the 
brain before the start of the trial, after surgery and before discharge 
(12)  the external validation of the sildenafil (pharmacokinetic – pharmacodynamic) PKPD 
model for the pharmacokinetics and the pharmacodynamic effects of sildenafil
Safety outcomes include adverse events due to the study drugs and the vasoactive-
inotropic support score (VIS).
Patients
Infants diagnosed with CDH who have PH in the first week after birth, are eligible for 
the trial if born at or after a gestational age of 34 weeks. The diagnosis of PH is defined 
as at least two of the following four criteria: (I) systolic pulmonary arterial pressure> 
2/3 systolic systemic pressure estimated by echocardiography. (II) RV dilatation/septal 
displacement, RV dysfunction +/- left ventricular dysfunction. (III) Pre-post ductal SpO2 
difference > 10%. (IV) OI >20. Exclusion criteria are a severe chromosomal anomaly which 
may imply a decision to stop or not to start life-saving medical treatment, severe cardiac 
anomaly expected to need corrective surgery in the first 60 days of life, renal anomalies 
associated with oligohydramnios, severe orthopedic and skeletal deformities, which are 
likely to influence thoracic, and / or lung development and severe anomalies of the central 
nervous system. Patients who are born in another center and transported with iNO are 
also excluded from the trial. Patients who received fetal interventions (trachea balloon 
placement) are not excluded. 
Following antenatal diagnosis, the parents are counselled and informed about the study 
by the clinician or research coordinator. Also, they receive a patient information letter 
and an informed consent form . If the patient is not born in a participating center or the 
diagnosis of CDH was not known, parents are counselled after the diagnosis of CDH and 
are informed about the study. Also, they receive written information and an informed 
consent form. This informed consent form contains consent for the trial and for collection 
of data and material for future research.
For the development of the protocol the SPIRIT reporting guidelines have been used (17). 
This publication is based on protocol version 4, June 13th 2018. 
Patient and public involvement
Patients and the public were not involved in the development of the trial protocol. 
However, CDH UK Sparks, as a parent organization,  has assessed and commented on the 
protocol and as provided start-up funding as also mentioned in the funding statement. 
This organization is and will be regularly informed on progress and results of the trial.    




Antenatal ultrasound data about the characteristics of the CDH are collected. These data 
include the observed/expected lung-head ratio, position of the liver and stomach and the 
amniotic fluid index. An MRI or an ultrasound is performed depending on local experience 
and possibilities. If an MRI is performed, the observed/expected fetal lung volume will be 
calculated. Also data on prenatal interventions are collected. In all mothers, a planned 
vaginal or caesarean delivery is pursued. 
Randomization, intervention and blinding
Participants will be randomized using ALEA, which is an online, central randomization 
service (https://www.aleaclinical.eu).  Allocation concealment will be ensured, as the 
service will not release the randomization code until the patient has been recruited 
into the trial, which takes place after all baseline characteristics have been added. ALEA 
randomizes the patient  with a computer-generated randomization list, made by the 
independent statistician of the Data Safety and Monitoring Board. Blocked randomization, 
with variable block sizes and stratification by center, is used to achieve equal distribution 
of the two interventions among the participants. 
Postnatally, infants are treated according to a standardized protocol for patients with CDH, 
which is implemented in all participating centers. This protocol was developed with the 
available evidence and consensus between the participating centers and was updated 
in June 2016 (10, 16). If the patient is diagnosed with PH in the first week of life, the 
patient will be allocated to one of the two study drugs (figure 1). iNO is provided by a tank 
connected to a ventilator. Different devices are used in different centers. Some centers use 
integrated systems, making it impossible to disconnect the iNO tank and replace it with 
another gas to facilitate a blinded intervention. Therefore, the study is open label. iNO is 
given with a starting dose of 20 ppm, which is the maximum dose (18, 19). Sildenafil is 
given intravenously, using a loading dose of 0.4mg/kg in 3 hours, followed by continuous 
infusion of 1.6mg/kg/day (20, 21). To wean the study drugs a standard protocol is followed 
(figure 2). The allocated drugs will be restarted as per protocol if criteria for its use are 
met again before the age of 14 days. To further standardize care, an inotropic support 
flow chart is included in the study protocol (figure 3). After day 14 treatment of PH will 
be at the discretion of the local medical team and the study drug can be changed to, for 
instance, sildenafil orally. The use of bosentan, milrinone and prostin next to the study 
treatment is allowed. The use of bosentan as add on therapy is allowed and is considered 
as PH treatment on day 14.The intervention will be prematurely stopped when the patient 
meets one or more of the defined failure criteria, described in point three of the secondary 
outcomes. Further treatment will then be at the discretion of the medical team and will be 
according to the standardized protocol(16). INO and sildenafil can both be given outside 
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the study protocol. An ECMO-procedure may then be started in centers where ECMO is 
available. Data of all patients are used in the intention-to-treat analysis.  
Follow up
After day 14, additional clinical data, such as time on ventilator support (days) and the 
use of drugs for the treatment of PH, are collected to answer the secondary outcome 
questions.  Also, echocardiographic measurements are taken at 6 and 12 months to 
evaluate the presence of chronic PH (table 1)
Data collection 
Echocardiography parameters are measured by local physicians, centrally collected and 
reviewed by two blinded independent physicians to reduce inter-observer variation. 
Demographic and neonatal characteristics as well as data on the clinical course of 
all patients are entered in a password protected web-based database in Rotterdam 
(OpenClinica).  Upon request the collected data will be available. All centers will keep a 
logbook of the number of non-participants, including the reasons for not participating. 
Study documents are securely stored at each study site for 15 years.
Laboratory testing
Blood, urine and tracheal samples are collected in most centers during the trial. Blood 
samples are collected before the start of the study and at different time points until day 
14. Some samples will be used to externally validate a NONlinear Mixed Effects Modeling 
(NONMEM) prediction model for sildenafil. The other samples will be used in future 
research on biomarkers to predict severity and outcome of PH in CDH patients. The 
samples are centrifuged for 6 minutes at 3000 rpm (22). Thereafter, the plasma is removed 
and stored at –20 degrees Celsius or colder. The total amount of blood taken is maximal 
2.5 % of the circulating volume. Blood sampling will only be done if a central or peripheral 
line is still present and/or in combination with routine laboratory measurements. This way 
blood sampling is a minimal burden for the patient. 
Tracheal aspirate for proteomic analysis is also collected at different time points during 
routine tracheal suctioning in ventilated patients. Protein profiling with proteomics is 
used to identify specific groups of proteins that are involved in the pathogenesis of PH. 
The tracheal aspirates is centrifuged for 6 minutes at 3000 rpm and stored at –80 degrees 
Celsius (23).   
Also, 8-hour urine is collected at different time points. Two samples of 5 ml are taken and 
stored at   –20 degrees Celsius or colder. 
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Patient with CDH Fill in CoDiNOS screening log
Pulmonary hypertension 
criteria, day 0-7







Sildenafil loading 0.4mg/kg in 
3 hours




 (table 1) 
Report SAE’s and SUSARs if 
applicable
Continue treatment, only 
stop when meeting failure 
criteria (and >1hr of sildenafil 
if applicable)




Drug stopped and inclusion 
criteria are met again  <14 
days: restart drug
Echocardiography at day 14
Follow up (table 1)
and
Echocardiography at 6 and 12 
months 
Figure 1 Trial flow chart
Flow chart showing the steps of the trial, from birth until 12 months. CDH: congenital diaphragmatic 
hernia; SAE: serious adverse event; SUSAR: suspected unexpected serious adverse event
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Figure 2 Protocol to wean study drug
Flow chart showing the protocol to wean off inhaled nitric oxide or intravenous sildenafil. iNO: 
inhaled nitric oxide; ppm: parts per million
Figure 3 Treatment flow chart of systemic hypotension
Flow chart that is added to the treatment protocol, showing the treatment plan for systemic 
hypotension. VA ECMO: veno-arterial  extracorporeal membrane oxygenation 
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Withdrawal of participants 
Parents may decide to withdraw from the study at any time without any consequences. 
The investigator can decide to withdraw a patient from the study for urgent medical 
reasons. In some cases, there may be exclusion criteria, which were not known before 
randomization. If this is the case, the patient will be withdrawn from the study after 
contacting the study coordinator. With consent of the parents data will still be collected, 
stored and analyzed to perform an intention-to-treat analysis. These children will be 
treated according to standard practice (10, 16).
Sample size calculation
The sample size calculation is based on a power analysis for the primary outcome, using 
previously published data on PH. . Lusk et al. showed that PH, defined as >2/3 systemic 
blood pressure measured on echocardiography, in CDH patients on day 14 has a positive 
predictive value of 0.8 for death, death or ventilation, and death or ventilator support. PH 
on day 14 is observed in 64% of CDH patients (24).  
Even though the definition of the primary outcome is not the same, we assume a similar 
outcome percentage of 64% for failing the primary outcome in our trial, the absence of 
PH on day 14 without pulmonary vasodilator therapy and/or absence of death within the 
first 28 days of life, in the iNO group. Our aim is to promote practice change, therefor we 
aim for a clinically significant difference For a 25% relative reduction to 48%, a sample 
size of 300 patients (150 patients per group) is needed to obtain a power of 80%. This will 
match a number needed to treat of 6.25. Taking missing data and the effects of correction 
for covariates into account, we adjust this sample size to 330 patients. In the collaborating 
centers 550 patients will be born in three years. Based on our earlier trial (CMV Versus HFO 
in Congenital Diaphragmatic Hernia; VICI trial) we expect to have an inclusion rate of 60%. 
Therefore, the inclusion of 330 patients should be reached in three years.
Data analysis 
The patients will be analyzed according to the group they are randomized to (intention-
to-treat analysis). A p-value (two-sided) < 0.05 is considered significant in all analyses. The 
primary endpoint  will be analyzed using multiple logistic regression with randomization 
arm, center, observed/expected head-lung ratio, position of the liver, side of the defect, 
defect size and ventilation modality as independent variables (25). If necessary, multiple 
imputation using the fully conditional specification method will be used to account for 
missing data in the independent variables. We will perform a sensitivity analyses with 
adjustment for the use of prostin and milrinone, to account for the effects of these 
vasodilators on PH.
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The following analyses will be performed for the secondary outcomes. The distribution 
of VIS score in all study participants will be compared between t=0 and t=12 hours after 
initiation of drug administration using a Wilcoxon signed rank test. The distribution of 
changes in OI and VIS score from t=0 to t=12 and t=24 hours  will be compared between 
the randomization groups with a Mann-Whitney test. The overall mortality in the first year 
of life will be compared between the randomization groups with Kaplan-Meier curves and 
the log-rank test. The number of treatment failures, the need for ECMO (in ECMO centers), 
and the need for medication for PH or chronic lung disease at discharge, and during the 
first year of life, will be compared between randomization groups with chi-square tests. 
The number of study drug free days at day 14, the number of ventilation-free days until day 
28, the fraction of days with need for medical treatment (excluding the study drug) for PH 
during the hospital admission, and the severity of chronic lung disease using the Bancalari 
definition, will be compared between randomization groups with Mann-Whitney tests. 
Deaths will be counted as the worst outcome in these analyses, in accordance with the 
intention-to-treat principle. The presence of  PH at 28 days/discharge, 6 and 12 months 
according to the echocardiographic parameters will be compared between randomization 
groups with a chi-square test. 
To externally validate the pharmacokinetic model of sildenafil and it active metabolite ( in 
NONMEM) Normalized prediction distribution errors (NPDE) and Visual Predictive Check 
(VPC) will be used. Furthermore, the model will be used to predict the drug concentrations 
from the new data set using simulations, in which we expect that the difference will be less 
than 20%. To assess whether there is a relationship between the concentration of sildenafil, 
its active metabolite and the clinical effects, such as OI, VIS score and echocardiography 
measures, a Mann-Whitney or Student’s t-test will be used. 
Safety reporting and trial oversight
All severe adverse events (SAEs) and suspected unexpected serious adverse reactions 
(SUSARs) are reported from the enrolment until 12 month follow-up. Persistent or significant 
disability or incapacity that was not expected with the given observed to expected lung 
to head ratio (O/E LHR) is evaluated as an SAE. An elective hospital admission is not a SAE. 
All SAEs and SUSARs are reported to the approving ethics committees in accordance with 
their requirements. We will report the SAEs and SUSARs that result in death or are life 
threatening within 7 days of first knowledge. All other SAEs and SUSARs will be reported 
within a period of maximum 15 days. Once a year throughout the clinical trial, we will 
submit a safety report to the approving ethics committees and competent authorities of 
the countries involved.
The trial will be monitored by qualified, independent monitors. The trial is classified as a 
trial with moderate risk and a specific monitoring plan is in place.  
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The data safety monitoring board will monitor the incidence of mortality on a continuous 
basis. If at some point a large difference in mortality, defined as an absolute risk increase 
of 25%, between the two treatment groups is noticed, the data safety monitoring board 
may recommend ending the study.
Insurance will cover compensation to patients who suffer harm from trial participation.
Ethics and dissemination 
Ethics approval has been granted by the local ethics committee in Rotterdam (MEC-
2017-324) and by the central Committee on Research Involving Human Subjects 
(NL60229.078.17) in the Netherlands. The trial will be submitted to the regulatory bodies 
and the local institutional review boards (IRB’s) in all participating countries. Important 
amendments will be communicated to all relevant parties.  The study will be conducted 
according to the principles of the Declaration of Helsinki, in accordance with the Medical 
Research Involving Human Subjects Act, and national rules and regulations on personal 
data protection. Parental informed consent will be obtained. The results of this study will 
be disseminated via peer-reviewed publications and implemented in the international 
guidelines for the treatment of newborns with CDH.  
Funding statement
This work was supported by CDH UK Sparks grant number 16EMC01 and by Stichting 
Sophia Kinderziekenhuis Fonds grant number S17-19. 
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GENERAL DISCUSSION
The research in this thesis describes various aspects of the clinical care for newborns with 
CDH, with emphasis on aspects of prediction, biomarkers and treatment. Most research 
has been conducted in a multicenter context within the CDH EURO Consortium, in the era 
after the widespread implementation of the CDH EURO Consortium guidelines (1). The 
consortium consists of 22 tertiary clinical centers inside and outside Europe with expertise 
in the treatment of patients with CDH. These centers collaborate to enhance the clinical 
care for these patients by developing clinical guidelines for the perinatal treatment of CDH 
patients, which are mostly based on expert opinion up till now, but also by developing 
an uniform and standardized international follow-up program (1, 2). Another important 
aspect of the mission of the consortium is to contribute to evidence based care by 
performing leading-edge research, such as the VICI trial and more recently the CoDiNOS 
trial (3)(chapter 7). CDH is a rare disease, making international and multidisciplinary 
collaboration essential to further improve clinical care for this patient group, as mortality 
remains around 25% even in the most experienced centers  
PREDICTION
Clinical prediction models
The severity of illness in CDH patients is highly variable and is dependent on the severity 
of lung hypoplasia and pulmonary hypertension, but also on the presence of additional 
anomalies. For both parents and caretakers early outcome prediction is essential to get 
insight in the prognosis of the individual patient. Prenatally, outcome prediction can guide 
parents and care providers in decisions regarding continuation of the pregnancy, the use 
of prenatal interventions such a temporary tracheal plugging (FETO), the referral to high-
volume centers for the delivery, and the use of specific postnatal therapy. Postnatally, an 
adequate early predictor can help parents to better understand the course of their child’s 
illness. Also, it can be used for a more individualized treatment strategy, and standardized 
reporting and benchmarking between centers. The Congenital Diaphragmatic Hernia 
Study Group (CDHSG) is a collaboration of centers from all over the world that voluntarily 
contribute data from CDH patients. These data are compiled to form an international 
registry and can be used for the development of prediction tools, among other things.  
To predict mortality a new easy tool, the preoperative chest radiographic thoracic area 
(CRTA) has been developed (chapter 2) (4). This tool seems to accurately correlate with 
the extent of lung hypoplasia and is a more reliable predictor of survival then the lung-to-
head ratio (LHR), but was not when compared to the more reliable observed-to-expected 
LHR. The CRTA adds to a variety of postnatal tools that have been developed to predict 
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survival in CDH patients (table 1). However, most are based on relatively small groups 
of patients, are difficult to apply or have not been validated (5-8). Brindle et al, and the 
CDHSG have developed and validated a simple early postnatal clinical prediction rule in 
a large cohort to identify low (<10%), intermediate (~20%), and high risk (~50%) of death 
in infants. This prediction model is based on birth weight, 5-minute Apgar score, severe 
PH on echocardiography, and the presence of cardiac and chromosomal anomalies (9). 
We found that in our group of CDH patients with standardized postnatal care the CDHSG-
rule was a fair predictor of survival (chapter 3) (9). This was in line with the validation 
of the prediction rule by Bent et al, showing a reasonable discrimination, but in their 
group an underestimation of mortality in the low risk group was seen (9, 10). This might 
be explained by the difference in health care systems in Europe and the United States. 
In Europe, centralized and standardized care is more common and many patients with 
CDH are increasingly born in high volume centers, which improves outcome (11). This 
might also explain the lowest mortality in patients born in the largest center of our study, 
although the variability in survival per year remains high even in the centers with the 
highest experience
We investigated the possibility to improve the model by incorporating both prenatal 
and postnatal variables in one model. Prenatal variables are able to adequately predict 
lung hypoplasia and the need for ECMO, but the prenatal assessment of O/E LHR or liver 
herniation as a marker for lung vascularization and postnatal PH seems less reliable (12). 
Although these prenatal variables have a role in predicting lung hypoplasia, in almost all 
postnatal prediction tools prenatal parameters are not taken into account. Interestingly, 
we found that liver herniation was the only prenatal variable that added to the power of 
the CDHSG model. This might be explained by collinearity and the absence of uniformity 
in the measurement of the O/E LHR.  Different O/E LHR measurement techniques at 
different time points in gestation are being used between centers, and there is a learning 
curve in the measurement of the O/E LHR (13). The longest diameter method even 
overestimates the O/E LHR up to 34% and has a larger inter observer variability compared 
to the tracing method (14). The standardization of measurement techniques such as O/E 
LHR, is essential to improve prediction. However, when using the tracing method the O/E 
LHR still only has an area under the curve (AUC) of 0.77 for survival (15). International 
training and standardization is needed and should be implemented within the context 
of one of the European Reference Networks, ERNICA. Measuring lung volumes on MRI 
seems promising (16). However, in many centers it is not possible to use MRI for this 
purpose, due to unavailability and costs. Unfortunately, not only prenatal variables lack 
standardization. Also the reporting of PH by echocardiography is not standardized and 
the echocardiographs are performed by a variety of medical specialists with significant 
differences in experiences. Furthermore, different definitions are being used. In Europe, 
the presence of PH is often defined as pulmonary pressures higher than 2/3 of the 
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systemic pressures instead of supra-systemic pulmonary pressures as often used in other 
centers (1, 9). Furthermore, the timing of measurement is very different between centers 
(9, 10). Although many European centers perform an echocardiography in the first 24 
hours of life, the Canadian centers perform the first echocardiography within 48 hours of 
life (1, 17). During the first days of life, pulmonary pressures decrease substantially due to 
physiological transition to extra uterine life. The timing of the echocardiography therefore 
influences its results. However, even with more consistent measuring techniques, timing 
and standardized reporting, outcome is also dependent on the later postnatal clinical 
course and therapy used in the individual patient. Standardized therapy improves 
outcome, and increases accurate prediction of outcome (11). Right now, the same 
treatment protocol is being used in most centers in Europe, initiated and guided by the 
CDH-EURO Consortium guidelines (1, 18). Also, more recently in Canada, standardized 
guidelines have also been developed (17). These guidelines are fairly similar, although 
the Canadian guidelines use stricter saturation and pCO2 limits and make a more explicit 
choice in inotropic support. However, even with standardized care there is a difference 
in outcome between centers. High-volume CDH centers have better outcomes as they 
are more experienced (19)(chapter 3). In conclusion, perfect outcome prediction is 
impossible. Nevertheless, clinical prediction scores like the CDHSG rule and our modified 
rule are useful for risk stratification. This can lead to a more individualized treatment plan, 
as shown in chapter 5, describing a spontaneous breathing approach in the delivery room 
in mild CDH cases.  
Lessons learned:
Many predictors for disease severity in CDH exist, but only a few have been externally 
validated.
Integrating the prenatal liver position and postnatal parameters increases the predictive 
power of the CDHSG model for mortality in CDH patients. 
Predictive prenatal and postnatal parameters and postnatal care are dependent variables
Future perspective:
Standardization of measuring techniques and reporting for several parameters is urgently 
needed to increase their predictive power.
Although the role of prediction models in the postnatal treatment of CDH patients is limited 
at the moment, patient selection based on prediction scores, initiating individualized 
care, should be further investigated as it can potentially improve outcome. It can prevent 
overtreatment in mild cases and might have a role in prevention and early treatment of 
PH and cardiac failure in severe cases. 
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Biomarkers
Biochemical biomarkers, solely or in a panel, are potentially useful for the prediction of 
CLD, PH and mortality in CDH patients. However, the ideal biomarker in CLD patients is 
yet to be found. We tested SIGLEC-5/14, BCAM and ANGPTL3, a panel of biomarkers which 
were found to be a sensitive prediction tool, at least for BPD in preterm infants (chapter 4)
(31). Although the panel was not predictive for CLD in CDH, it did predict mortality in our 
population with an AUC of 0.76. Siglecs help immune cells to distinguish between “self” 
and “non-self”. SIGLEC-5/14 has a role in the regulation of the immune response in the lung 
and is associated with Group B Streptococcus infections in preterm infants and newborns, 
but also with the degree of tissue damage and the amount of inflammatory exacerbations 
in COPD in adults (32, 33). BCAM is associated with impaired lung development and 
airway branching (31). ANGPTL3 has a regulatory role in the angiogenesis of the lung (34). 
Although these biomarkers did have an association with mortality in CDH patients, it was 
not as strong as the association with BPD in preterm infants. Both BPD and CLD reflect 
an alteration in lung development, unlike chronic lung disease in adults such as COPD. 
However, BPD in preterm infants and CLD in CDH patients differ substantially. Although 
the definition of BPD is still controversial, to diagnose BPD by definition the infants are 
born preterm in contrast to the older definition in which BPD could also be diagnosed 
in term infants who needed oxygen supplementation on day 28 postnatal age (35). The 
substrate for BPD in preterm infants is a combination of a structurally immature lung 
and lung injury and subsequent repair. In the preterm infant the injury can be caused 
by inflammation, due to chorioamnionitis, oxygen exposure and mechanical ventilation. 
Developmental disruptions, such as growth restriction and nicotine exposure, play a role 
too, impeding the alveolarization of the lung (36). BPD is associated with pulmonary 
vascular remodelling causing PH. Although BPD and PH partly have the same risk 
factors, there is growing evidence that PH in preterm infants has a foetal “origin” that is 
caused in part by maternal vascular disease during pregnancy (37). In contrast to BPD 
and PH in BPD, a structural lung defect in early foetal development, possibly due to 
changes in the retinoic acid signalling pathway, causes pulmonary hypoplasia and PH 
in CDH patients. This is characterized by thickened alveolar walls, reduced alveolar air 
spaces and an increase in interstitial tissue (38). The differences between BPD and PH are 
underlined by the effect of surfactant on the initial lung pathology at birth. In contrast 
to the premature infant, surfactant does not improve outcome in CDH patients because 
surfactant maturation in CDH lungs is not delayed (39, 40). Pulmonary hypertension in 
CDH is characterized by hypermuscularization of the midsized and large vessels and 
neomuscularization of the small capillaries in an incomplete capillary bed. These changes, 
as well as the expression of markers associated with more contractile smooth muscles, are 
already seen early in gestation, and can be explained by altered behaviour and maturation 
of pericytes, the precursors of smooth muscle cells (41, 42). Although inflammation has a 
clear role in BPD, this is not obvious in CDH patients. Interestingly, not ANGPTL3 with a 
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role in angiogenesis, but SIGLEC-5/14, a marker involved in the immune response, could 
identify mortality. We evaluated these markers on day 1 and 3, but the exact moment of 
sampling on day 1 could be soon after birth or at 24 hours. All infants with CDH received 
intensive care treatment, consisting of intubation and ventilation with 100% of oxygen 
initially, parenteral nutrition and if needed inotropic support, antibiotics and vasodilating 
drugs. One could argue that these early postnatal influences could have already triggered 
inflammation. Earlier biomarkers, such as samples taken from the umbilical cord, might 
be more suitable. However, the finding of SIGLEC-5/14 as a biomarker for mortality in 
CDH raises the question how much harm is done with the current treatment strategies. 
This endorses the importance of individualized care, balancing the benefit and the harm. 
These inflammatory biomarkers might also guide us towards a more restrictive approach 
to oxygen therapy, since high alveolar oxygen concentrations cause pulmonary edema, 
and increase inflammatory markers and cell necrosis (43).     
SIGLEC-5/14, BCAM and ANGPTL3 were derived from proteomic screening in preterm 
infants (31). Instead of analyzing a single biomarker or a group of known biomarkers, 
proteomics might also increase our knowledge in which proteins are relevant in the clinical 
course of CDH. Proteomic profiling offers complementary information to genomics and can 
be used without any preliminary hypotheses. Protein function and abundance is dependent 
on genomic expression, but also on multiple posttranscriptional and posttranslational 
mechanisms (44). By using whole proteome screening at different time points, relevant 
pathways and proteins might give a more detailed insight in the pathophysiology of CDH 
and the effects of therapy. Using proteomic screening in tracheal aspirate, CDH patients 
could be separated from healthy controls, intrauterine via amniotic fluid, as well as in the 
first 48 hours of life (45, 46). This may be the first step towards the identification of different 
disease phenotypes and subsequently a protein profile-specific treatment plan. But tracheal 
aspirate sampling is an invasive procedure. Exhaled breath condensate (EBC) analysis, 
collected by cooling exhaled breath, might be a reliable non-invasive method. However, 
there is no standardization in EBC collection for intubated infants at this moment (47).
Lessons learned
BPD in preterm infants and CLD in CDH patients are different entities. The panel of 
biomarkers SIGLEC-5/14, BCAM and ANGPTL3 can predict mortality but not CLD in 
CDH patients. SIGLEC-5/14, an inflammatory biomarker, was the strongest predictor of 
mortality.
Future perspectives
With proteomic screening at different time points, derangements in relevant pathways 
might give a more detailed insight in the pathophysiology of CDH and the effects of 
therapy. 
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Over time the focus of therapy in CDH has changed. Until the 80’s CDH was considered a 
surgical emergency (figure 1). Thereafter preoperative stabilization because mainstream, 
focusing on correcting acidosis and hypoxia (48). However, aggressive ventilation 
strategies cause barotrauma in the hypoplastic lungs. In 1995 Wung et al reported a 
respiratory strategy focusing on the prevention of hyperventilation and hyperinflation to 
minimize iatrogenic lung injury and exacerbation of pulmonary hypertension (49). Since 
then this has been adopted worldwide and surgical closure has been transformed into an 
elective procedure in “stable” patients. However, it wasn’t until the late 2000 though, that 
the VICI trial started, the first RCT in CDH patients, comparing conventional ventilation 
with high frequency ventilation (50). Primary outcome was chronic lung disease and/or 
mortality on day 28. However, inclusion rates of 400 patients were never met, the study 
was halted after 171 patients and a study period of 5 years. The study showed no difference 
in primary outcome between ventilation modes, but was heavily underpowered. Other 
outcome parameters, including ventilation time, inotropic support and need for ECMO, 
favored conventional ventilation (3). Also  prenatal interventions, first open surgery and 
tracheal clipping and later fetal endoscopic tracheal occlusion (FETO), were developed to 
increase lung growth. The first RCT did not show improvement of survival or morbidity 
in fetuses with severe CDH, and more infants were born prematurely in the intervention 
group (51). The disappointing results of the trial at that time resulted in a moratorium on 
tracheal plugging at least in the USA. As technical progress made the procedure more 
safe, the so-called TOTAL trial was created and conducted mainly by a small number of 
expertise centers in Europe; Leuven, Barcelona and London. Currently, the TOTAL trial, 
an international RCT is investigating FETO. In the moderate (NCT00763737) CHD group 
the trial is completed and we are awaiting results. In the severe (NCT01240057) CDH 
group, the trial is still recruiting. Nowadays the focus has shifted from the hypoplastic 
lung towards PH. At this time two RCTs are recruiting CDH patients in the search for the 
best initial therapy for PH, the CoDiNOS trial (chapter 7) and the “Milrinone in Congenital 
Diaphragmatic Hernia” trial (NCT02951130). There are also a few trials on their way that 
focus on physiological based cord clamping, such as the PinC trial (NCT04373902) and the 
CHIC trial (NCT04429750), with the aim to decrease the incidence of PH. (table 2)
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Figure 1. Focus of research and therapy in CDH patients “shifting the paradigm”
Table 2. Randomized controlled trials in CDH currently recruiting 
RCT Started 
in 
Intervention Primary outcome 
FETO 2008 Fetoscopic endoluminal tracheal 
occlusion with a balloon versus 
expectant management 
to increase lung size




2016 Ventilation with different tidal 
volumes 
Change in Pressure Time 
Product of the diaphragm
CoDiNOS
 
2017 Sildenafil versus iNO treatment of PH
PinC 2020 Physiological based cord clamping 
versus direct cord clamping 
to prevent development 
of PH
CHIC 2020 Physiological based cord clamping 
versus direct cord clamping 
to prevent development 
of PH
In Chapter 7 we describe the CoDiNOS trial protocol, comparing intravenous sildenafil 
with iNO in the treatment of PH in CDH patients. When performing an RCT in infants 
using a pharmacological intervention, it is essential to first establish an adequate dosing 
regimen to be able to evaluate efficacy. Although pharmacokinetic drug testing in adults 
is very common, in infants dosing regimen are often an extrapolation from adult data, 
only corrected for body size (52). This assumes that fractioning of the dose will lead to 
similar plasma drug levels as it also assumes that, besides body composition, children 
have similar renal, gastrointestinal and hepatic function. This can result in over- and under 
dosing, leading to toxicity or reduced efficacy (53). Before starting the CoDiNOS trial we 
developed a pharmacokinetic model of sildenafil in infants with CDH (chapter 6). We found 
that the dosing regimen commonly used in newborns with PPHN was also applicable to 
136   |   Chapter 8
CDH patients. A loading dose of 0.4mg/kg in 3 hours followed by a continues infusion of 
1.6mg/kg/day achieved adequate sildenafil plasma levels. Steinhorn et al found this dosing 
regimen in a dose-escalation trial in infants with persistent pulmonary hypertension of 
the newborn (54). Although numbers were too low to find a strong correlating between 
plasma concentration and clinical effects, plasma concentrations over 50µg/l seemed to 
decrease the oxygenation index. In our cohort plasma concentrations were 190 µg/l and 
higher after 3 hours. However, numbers were too low to find any correlation between these 
concentrations and the oxygenation index. Samples collected during the CoDiNOS trial 
will give more insight in the dose-response correlation of sildenafil in CDH patients as well 
as other pharmacodynamic effects. Pharmacodynamic evaluation is not only important 
for its effect but also for its side effects. Currently, sildenafil is given with a loading dose 
over 3 hours, because of the risk of hypotension. Consequently, the first clinical effect of 
sildenafil can probably only be seen after 1 hour of infusion, which is a long time for this 
instable group of patients with CHD and PH. Unintentionally, the loading dose of sildenafil 
was given as a bolus to one of our CDH patients. Subsequently the saturation improved 
from 84% to 98% with a only a slight decrease of blood pressure from mean 48mmHg 
to mean 44mmHg (figure 2). Possibly the positive effect of sildenafil on PH and therefor 
cardiac output compensates the negative effect on blood pressure due to vasodilatation 
in CHD patients with good cardiac function.     
Figure 2. Bolus of sildenafil in newborn with CDH
Blue line = oxygen saturation, black line = respiratory rate, green line = heart rate, red line = blood 
pressure
Although the CoDiNOS trial is still recruiting patients and evidence suggests that 
sildenafil can play a role in the treatment of PH in CDH, one could argue that, from a 
pathophysiological standpoint, it would be more logical to compare drugs that act on 
different pathways, instead of comparing drugs that both act on the nitric oxide-cGMP 
pathway. Also, there seems to be no apparent alteration of this pathway in CDH patients, 
decreasing the change of finding an effective drug (55). Drugs that affect the endothelin 
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pathway might be more successful. CDH patients show an increase in endothelin A and B 
receptor expression and ECE-1 enzyme. This enzyme is responsible for the conversion of 
endothelin-1 to its active form (55). CDH patients with PH have higher endothelin-1 plasma 
levels than CDH patients without PH (56). However, endothelin receptor antagonists are 
still only available in oral form, making them unsuitably for the treatment of CDH patients. 
The prostacyclin pathway seems to be altered in CDH patients too. Mous et al found a 
decrease of prostaglandin-I2 receptor expression, which would explain the negative effect 
of prostacyclin derivates on PH in CDH patients, although results are conflicting (55, 57, 58). 
All drugs available for PH in infants, children and adults influence one of the three pathways. 
However, the etiology of PH differs widely between age groups but also between different 
diseases and none of these drugs can resolve PH as a whole (one drug fits all). The focus 
of new drugs might need to be outside these pathways. Possibly proteomic screening will 
give us a new entry for drug development. For instance, in adults with pulmonary arterial 
hypertension bromodomain-containing protein 4 (BRD4) has been identified as driver 
for hyperpoliferative, apoptosis-resistant and inflammatory phenotypes of endothelial 
cells and smooth muscle cells. BRD4 is a member of the bromodomain and extra-terminal 
motif (BET) family. RVX208, an BET inhibitor, reverses these phenotypes in vitro and in rat 
models. A clinical trial has not been performed though (59). Proteomic screening can also 
give more insight in the effects and side effects of treatment. 
It is to be questioned if an RCT as we know it in its present form, in orphan diseases such as 
CDH, is the optimal tool to collect evidence based information. The VICI trial had recruiting 
issues due to the lower than anticipated recruitment rate and a lack of financial resources, 
which affected the organization of the research infrastructure in participating centers. 
Also in the CoDiNOS trial serious recruiting issues exist. We planned to include 330 
patients in a time frame of 3 years. However, at the time of writing, we have included 11 
patients in 3 years. This is partly caused by lower than anticipated recruitment rates due to 
strict inclusion criteria. It is very important to select the right patients when performing an 
RCT. The potential benefit and harm of an intervention should be taken into account and 
including mild cases will dilute the effect of an intervention. Although echocardiogram 
is often perceived to be the best diagnostic tool in newborns, the incidence of PH on 
echocardiogram on day 1 of life overestimates the incidence of clinical relevant PH, 
because high pulmonary pressures are still part of the physiological transition. We only 
include infants with clinically relevant PH, defined as PH on echocardiogram and clinical 
signs of PH, decreasing the incidence of PH from 60% to around 30%. Other important 
recruiting issues are a delay in National Drug Authority approval in participating countries, 
issues with legislation and insurance, and limited funding. Performing an RCT in pediatric 
critical care is challenging, especially when a high number of centers is needed due to low 
volumes, like in the CoDiNOS trial. Lack of funding and time are known barriers to conduct 
an RCT in pediatric critical care. Collaborating in a research network, such as the CDH EURO 
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Consortium, increases the chance of success (60). However, regulations to conduct an RCT 
in pediatrics, especially drug interventions, are increasingly stringent. For example, many 
countries and health care institutions force researchers to use a Clinical Trial Organization 
when conducting a trial. However, these organizations are often very expensive, swallowing 
a major part of the budget of investigator-led trials. Interestingly enough, investigator-
initiated research is significantly more frequently cited than industry-led trials in critical 
care medicine (61). This proves that investigator-initiated research is very important as 
it is more clinically relevant and has more impact on clinical practice. Legislation should 
not further complicate investigator-initiated research but should focus on stimulating 
these relevant trials. This was acknowledged in the revision of Directive of the European 
Commission in 2014, but does not seem to have resulted in a substantial practice change 
(62). However, in 2017 European Reference Networks were launched in response to a 
European Commission call. The goal of these networks is to improve healthcare for rare 
diseases in Europe, focusing on medical training and research, information dissemination 
and evaluation. One of these networks is ERNICA, the European Reference Network for 
rare  Inherited and  Congenital (digestive and gastrointestinal)  Anomalies. Although 
the CDH EURO Consortium is a robust network, affiliating with ERNICA can potentially 
increase funding and logistical support for RCTs in the future by merging funding and 
resources. To further increase the clinical relevance of trials, patient organizations are 
increasingly involved in the funding and development of trials, especially in investigator-
initiated trials. The CoDiNOS trial is funded for an important part by CDH-UK Sparks, the 
CDH patient organization from the United Kingdom.      
New statistical approaches might also increase the feasibility of controlled trials. For 
instance, one could add real-world controls to a trial, decreasing the number of included 
patients needed to achieve statistical significance. The real-world controls consist of 
patients whose parents either chose not to participate in the trial or were not included 
due to logistical and organizational issues. Looking at the VICI-trial, more than 425 of the 
619 patients who were treated in the VICI trial centres during the study period were not 
included in the trial. These real-world controls should be highly comparable to the VICI 
patients, because they share the same treatment period, the same treatment guideline 
(i.e. the CDH EURO consortium guidelines) and they were treated in the same centres. 
Most of the patients not participating were initially treated with conventional mechanical 
ventilation, as this was the standard of care at the time. When combining data from the 
randomized VICI trial with the observational data from patients who did not participate in 
the trial, one needs to account for potential differences in baseline patient characteristics 
and other biases that may arise from the inclusion of non-randomized data. Different 
statistical techniques such as dynamic borrowing can be used for this purpose (63). This 
approach would lead to revised estimates of the treatment effect of ventilation mode 
on the primary endpoint with greater statistical power and precision. Using real-world 
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controls can increase the feasibility of RCTs in many rare patient population substantially. 
However, to our knowledge it has not been used in clinical research.  
One could also decrease the number of patients needed by changing the primary 
endpoint from a dichotomous and cross-sectional endpoint to a more sensitive endpoint, 
incorporating repeated measurements or having a more informative scale (e.g., ordinal 
or continuous). This increases the statistical power to test the impact of an intervention 
on the patient’s outcome. This is especially relevant for CLD, which was defined in the 
VICI trial as the need for any respiratory support on day 28, without taking into account 
the amount and the duration of respiratory support. Several additional measurements 
collected from VICI trial patients could be used to define more informative endpoints. 
This can include ordinal endpoints such as the level of ventilation support, continuous 
variables such as amount of oxygen support, and derived endpoints such as time to 
discharge or time to reduction of ventilator support. Based on these more informative 
endpoints, multiple hypothesis testing with improved statistical properties compared to 
the original primary analysis can be applied. One can combine the endpoints in a single 
composite endpoint, for instance by defining a score that incorporates information from 
several endpoints and also accounts for mortality, but one can also test each endpoint 
separately. Specific statistical approaches to account for multiplicity for the testing of 
multiple, repeatedly measured endpoints will be needed, such as the multiple marginal 
generalized estimating equation models (GEE) method (64). The GEE method can 
incorporate endpoints on different scales (e.g. death and oxygen support), repeated 
measurements, and measurements recorded at a single time point only, while accounting 
for the correlation between endpoints to maximize the power of statistical tests.
Lessons learned
Pharmacokinetics of sildenafil and its metabolite is similar in newborns with PPHN and 
CDH and only postnatal age influences its clearance.
Controlled trials in children with orphan diseases are difficult to perform for various 
reasons, although these trials have a large clinical impact. Trials executed by a consortium 
have the largest change to succeed.  
Future perspectives
Although the pharmacokinetic profile of intravenous sildenafil in patients with CDH is 
more clear, little is known of its pharmacodynamic profile. The results of the CoDiNOS trial 
will give more insight in the PKPD model of sildenafil and it metabolite.
New drug trials should focus on the endothelin pathway as this pathway seems altered 
the most in CDH patients. However, an intravenous dosage form needs to be developed 
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first. Also, proteomic screening will potentially reveal new pathways that can be used for 
drug development.   
Newly developed statistical tools are currently not implemented in clinical research. 
However, these tools can decrease the number of patients needed to answer the research 
question. 
Respiratory support
Therapy in CDH patients is standardized in European centers since the introduction of the 
CDH EURO Consortium guidelines in 2010. This has increased survival from 67% to 88% 
(1, 18). Most of the content of the guidelines is based on expert opinion, not on evidence. 
With reliable prediction models one can select specific patient groups to change common 
practice, because one size probably does not fill all. According to these guidelines all 
CDH patients are immediately intubated and ventilated with 100% oxygen after birth. 
One of the keystones of the guidelines is gentle ventilation to prevent lung damage 
of the hypoplastic lung and to decrease the negative impact of positive intrathoracic 
pressure on pulmonary perfusion by limiting inspiratory peak pressures (1, 17, 65, 66). 
We have introduced a spontaneous breathing approach (SBA) in the delivery room for 
patients with mild CDH, using the prenatal prediction criteria for isolated left sided CDH, 
O/E LHR of 50% or higher, and an abdominal position of the liver (chapter 5). For this 
subgroup of CDH patients, intubation and mechanical ventilation immediately after birth 
has potential unnecessary side effects. Positive pressure ventilation can cause lung injury 
due to a combination of barotrauma, volutrauma, atelectrauma and hyperoxia (67). Also, 
with a successful SBA, stress, pain and the need for sedation is reduced and consequently 
postnatal parent-infant interaction is improved. We found that in this group with relatively 
mild disease, SBA is feasible. In 40% the SBA was successful, in the other 60% it did not 
seem to cause harm. More research is needed to explore the effect of an unsuccessful SBA, 
to evaluate the patient selection criteria and to externally validate these results. Although 
an RCT would be the most powerful tool to prove the role of an SBA in mild CDH patients, 
this does not seem feasible due to low patient numbers. 
Lessons learned
Patient selection to make an individualized treatment plan is feasible and resulted in an 
SBA in patients with mild CDH. The SBA was successful in 40% of the patients. 
Future perspectives   
The effect of an unsuccessful SBA should be further investigated, as well as the patient 
selection criteria. The results also need external validation.
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The role of the heart
Using prediction to tailor therapy as we did (chapter 5), could now become a logical step in 
the optimization of the treatment of CDH patients. In pediatric oncology risk stratification 
is an important tool to individualize the treatment protocol for patients (68). However, it is 
important to use the right tools to stratify the patient. In CDH patients, the focus has been 
on the lungs and the vascular bed. However, growing evidence shows that we should 
not overlook the heart (figure 1). In a large group of CDH patients 39% had some degree 
of ventricular dysfunction, right, left or both on the initial echocardiogram. Especially 
left ventricular (LV) dysfunction and dysfunction of both ventricles was associated with 
increased mortality (69). Even in the “low-risk”- group, defined as defect size A/B without 
other structural anomalies, diminished LV function, as well as severe PH, were strong 
independent predictors of outcome (70). PH is partly responsible for cardiac dysfunction 
in CDH patients. The right ventricle dilates and shows diastolic dysfunction due to the 
increase in afterload. Septal displacement impairs the left ventricle function. But in 
left-sided CDH patients the left ventricle is often also hypoplastic, further increasing its 
dysfunction (71). Also in right-sided CDH patients the right ventricle is decreased in size 
(72). Possibly immediate cord clamping in the delivery room also contribute to cardiac 
dysfunction. Before cord clamping, oxygenated blood in the umbilical veins shunts via 
the ductus venosus and foramen ovale to the left atrium, guaranteeing venous return 
to the LV. Cord clamping separates the newborn from its oxygen source and from the 
blood flow required to maintain LV preload. At the same time, LV afterload increases as the 
low-resistance circulation of the placenta is removed (73, 74). As a result, cardiac output 
decreases. Various trials, such as the PinC trial (NCT04373902), are currently recruiting, to 
investigate the effect of physiological based cord clamping on PH and cardiac function 
(table 2). 
CDH patients with PH and a diminished LV function are more often unresponsive to 
intravenous sildenafil and iNO as shown by Kipfmueller et al and Lawrence at al (75, 
76). It is assumed that, although pulmonary vascular resistance decreases, the failure 
of the LV is exacerbated by the increase in pulmonary venous return (77). Milrinone, a 
phosphodiesterase 3 inhibitor, improves diastolic function and possibly has a direct effect 
on PH, potentially making it a very suitable drug for the treatment of both right ventricular 
(RV) and LV dysfunction in CDH patients. However, in a small group of CDH patients milrinone 
did not improve outcome (78). Although the RCT “Milrinone in Congenital Diaphragmatic 
Hernia” trial (NCT02951130) focusses on the effect of milrinone on oxygenation index, it 
will also increase our knowledge in the role of milrinone in supporting the heart in CDH. 
Also vasopressors, such as vasopressin, could potentially play a role in LV dysfunction. 
Vasopressin has shown to improve hemodynamics in CDH patients (79). The mechanism 
of improvement is unclear, but may be explained by improved biventricular function in 
response to an increase in LV afterload without adverse effects on pulmonary vascular 
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resistance. When LV dysfunction persists, ECMO can be used as a last resort. Later on, in 
childhood, an increased ejection fraction and a reduction of the stroke volume of the LV is 
seen in CDH patients, without decreased perception of fitness (80).  
The severity of early RV diastolic dysfunction is correlated with length of ventilator support, 
length of stay and mortality (81). Interestingly enough, pulmonary artery pressure is not 
associated with the same outcome, suggesting that the right ventricle itself plays an 
important role in disease severity (82). RV diastolic dysfunction often improves after 2 to 3 
days, but can deteriorate after surgery (81). First step in the treatment of RV dysfunction is 
reducing afterload by treating PH. The next step might be a cardiotrope such as milrinone. 
If severe RV dysfunction persists ECMO treatment might be needed (71). RV function in 
CDH patients seems to be altered years after the surgical repair (83). The clinical impact of 
this alteration into adulthood is unclear. The trial “Growing up after surgery for Congenital 
Diaphragmatic Hernia (CDH): Problems for life?” is currently recruiting, evaluating cardiac 
function, among other things, in young adults with CDH (NTR NL7688).  
Although more research is needed, one could argue that in the treatment of CDH, the 
cardiac function should also be assessed to stratify the patient and incorporate the cardiac 
function in the treatment plan. Also, surgery in CDH patients is typically planned after 
hemodynamic stabilization, possibly one should take diastolic dysfunction into account 
before performing surgery (84). However, Tanaka et al showed that early surgery, within 
24 hours, improved diastolic dysfunction in CDH patients, increasing the preload of the 
left ventricle, which increases its contractibility (85). 
However, like in PH, the assessment of cardiac function on echocardiogram is not 
standardized. Different measurement techniques with various degrees of difficulty to 
measure and analyze are being used. Also, some of these measurements are load or 
heart rate dependent (71). Therefore, in the CoDiNOS trial we use a standardized panel 
of measurements to assess the pulmonary pressures and the heart. One could argue that 
clinical parameters should also be incorporated in the assessment of cardiac function 
as the pattern of cardiac dysfunction can change and an echocardiogram will not be 
readily available any time of the day and is fairly invasive for a newborn in intensive care. 
Although these parameters are surrogate markers for cardio-vascular status, integrating 
parameters such as pre- and postductal saturation, blood pressure and heart rate and 
its variation in a real-time multimodality model might help us to see very early signs 
of PH or cardiac dysfunction. Multimodality monitoring is currently being investigated 
in CDH patients for a different purpose, in the NEMO trial (NTR7160). The NEMO trial 
focusses on peri-operative neuromonitoring and growth and neurodevelopment at the 
age of 2 years. Although a single neuromonitor, such as NIRS, was not related to clinical 
outcome or prognosis, the integration of several monitors into a multimodality model 
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using high frequent measurements might substantially increase its clinical relevance (86). 
This concept of multimodality monitoring might also be useful for other clinical outcome 
parameters such as PH and cardiac dysfunction. In neonatal intensive care attempts have 
been made to develop multimodality hemodynamic monitoring. However there are still 
some important limitations, such as the use of surrogate measurements because direct 
measurement of hemodynamic measurements is impossible in newborns, but also 
limitations in technology and costs (87). High density monitoring might also give more 
insight in the effect of oxygen in CDH patients, because one could use an area-under-the-
curve analyses instead of a cutoff analyses (88). This longitudinal and cumulative approach 
probably better addresses the effect of hyperoxia on the lung and pulmonary vasculature. 
Lessons learned
Ventricular dysfunction of both the RV and LV can be seen in CDH patients and is predictive 
for outcome.
Future perspectives 
First, a golden standard for echocardiographic assessment of cardiac dysfunction should 
be developed. As this is not a continues monitor, a multimodality model might help to 
evaluate cardiac function and PH in real-time. 
The treatment of the ventricular dysfunction needs to be further investigated, with and 
without the presence of PH as the treatment of PH can further exacerbate LV dysfunction. 
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SUMMARY
The research described in this thesis addresses several aspects of the perinatal and 
neonatal management of patients with CDH. Most research is conducted in cooperation 
with members of the CDH Euro Consortium, a clinical and scientific collaboration between 
tertiary medical centers in Europe with expertise in the treatment of CDH patients. 
PART I Introduction
In Chapter 1 the historical background of CDH is described. Also the importance of 
predicting outcome is discussed. Thereafter, prenatal parameters, such as observed 
to expected lung-to-head ratio (O/E LHR), and their clinical relevance are explained. 
Additionally, postnatal parameters and models are discussed, next to the role of 
biochemical biomarkers in the prediction of chronic lung disease (CLD) and pulmonary 
hypertension (PH) in CDH patients. The focus of the international guidelines is described, 
preventing ventilator induced lung injury and establishing cardiovascular stability. 
Subsequently, the three mayor pathways involved in regulation of the pulmonary vascular 
resistance are explained and the drugs that act on different steps of the pathway. Lastly, 
the survival, but also the morbidity and long-term follow-up are discussed briefly. 
PART II Prediction   
Chapter 2 presents an editorial on a new prediction tool, the preoperative chest 
radiographic thoracic area (CRTA), tracing the lung on an anterior-posterior chest x-ray. 
The role of CRTA is discussed and placed in a broader perspective of prediction tools 
used in CDH patients. This new tool seems to be a relatively reliable new tool, but will 
need additional validation. Many tools used in this group of patients struggle with 
the same issues; they were only tested on small groups, are difficult to apply or don’t 
have a standardized definition or measurement method. The latter holds for PH on 
echocardiogram and the O/E LHR, decreasing its reliability. 
In Chapter 3 the Congenital Diaphragmatic Hernia Study Group prediction rule, an early 
model to predict mortality in CDH patients, is validated with a cohort of 343 CDH patients 
born in 4 large European centers. All centers use the same standardized CDH-EURO 
Consortium treatment protocol. In this group the rule shows a fair predictive performance. 
To further improve the rule, the pre- and postnatal parameters of 620 CDH patients 
are used to modify the rule. Interestingly, only liver herniation is of additional value to 
improve the rules ability to predict mortality in CDH patients. Also, the variable “missing 
Apgar score” is taken out of the model as it is not of significant value in our population.  
In addition to the discovery of novel early biomarkers SIGLEC-14, BCAM, and ANGPTL3 
to predict bronchopulmonary dysplasia in preterm infants, these biomarkers are tested 
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in preterm infants, CDH patients and adults in Chapter 4. The role of these biomarkers 
in predicting BPD in preterm infants is validated and protein concentrations correlate 
with the duration of mechanical ventilation, oxygen supplementation and structural lung 
changes. Although chronic lung disease in CDH patients cannot be predicted, it does 
separate surviving from non-surviving CDH patients and SIGLEC-5/14 seems to predict 
PH. In adults the biomarkers cannot separate patients from healthy controls. 
PART III Treatment
In Chapter 5 a novel, more individualized approach in the delivery room is described. 
In contrast to common practice, newborns with mild CDH, defined as isolated left-sided 
CDH, O/E LHR ≥50% and intra-abdominal liver position, are not routinely intubated in 
the delivery room, but only when they develop respiratory failure. This approach is 
successful in 40% of the patients, decreasing possible iatrogenic complications of prompt 
intubation, while it does not seem to negatively affect outcomes in the patients who 
develop respiratory failure. 
To develop an adequate dosing regimen of intravenous sildenafil in CDH patients, in 
Chapter 6 a pharmacokinetic model is developed, using samples from 23 infants with 
CDH. A two-compartment disposition model of sildenafil and a one-compartment 
disposition model of desmethyl sildenafil is observed. Only postnatal age increases 
sildenafil clearance and sildenafil is tolerated well in this relatively small group. The widely 
used loading dose of 0.4mg/kg in 3 hours, followed by 1.6mg/kg/day continues infusion, 
achieves appropriate sildenafil plasma levels in CDH patients.
The related trial protocol of the CoDiNOS trial is discussed in Chapter 7. The CoDiNOS 
trial is an international randomized controlled trial in which intravenous sildenafil is 
compared to inhaled nitric oxide for the first-step treatment of PH in neonates with CDH. 
We hypothesize that intravenous sildenafil is superior to inhaled nitric oxide. Primary 
outcome is the absence of pulmonary hypertension on echocardiography on day 14 
without therapy and without treatment failure and/or death within the first 28 days of 
life. With a sample size of 330 patients we will be able to detect a 25% relative difference 
in outcome between both drugs. Secondary outcome parameters are the need for 
ECMO, time on intervention drug, the incidence of chronic lung disease and the external 
validation of the pharmacokinetic model for sildenafil, among others.   
PART IV Discussion and summary
The general discussion in this thesis addresses the association of this research with the 
literature, as well as the implications for future research in CDH and in orphan diseases 
in general. The strengths and the weaknesses of the research are discussed. The main 
recommendations are: 
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- Standardization of measuring techniques and reporting for several prenatal and 
postnatal parameters is urgently needed, for prediction and for evaluation of therapy.
- Although the role of prediction models in the postnatal treatment of CDH patients 
is limited at the moment, patient selection based on prediction scores, initiating 
individualized care, should be further investigated as it can potentially improve outcome. 
It can prevent overtreatment in mild cases and might have a role in prevention and early 
treatment in severe cases. 
- Multicentre research collaboration is essential in orphan diseases such as CDH. However, 
an RCT in this population is very challenging. Newly developed statistical tools are 
currently not implemented in clinical research. These tools can decrease the number of 
patients needed to answer the research question and should be further investigated and 
implemented. 
- The treatment of the ventricular dysfunction needs to be further investigated, with and 
without the presence of PH as the treatment of PH can further exacerbate LV dysfunction. 
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NEDERLANDSE SAMENVATTING
Het onderzoek in dit proefschrift beschrijft verschillende aspecten van de perinatale 
en neonatale behandeling van patiënten met congenitale hernia diafragmatica (CHD). 
Het meeste onderzoek is verricht in samenwerking met de leden van het CDH EURO 
Consortium, een klinisch en wetenschappelijk samenwerkingsverband tussen tertiaire 
medische centra in Europa met expertise in de behandeling van CHD patiënten. 
Deel I Introductie
In Hoofdstuk 1 wordt de historische context van CHD beschreven. Ook het belang 
van predictie wordt bediscussieerd. Vervolgens worden prenatale parameters, zoals 
geobserveerde-versus-verwachtte long-hoofd-ratio (O/E LHR), en de klinische relevantie 
besproken. Daarna worden postnatale parameters en modellen besproken, als ook 
de rol van biochemische biomarkers voor de predictie van chronische longziekte en 
pulmonale hypertensie (PH) in CHD patiënten. De focus van de internationale richtlijnen, 
het voorkomen van beademings-geïnduceerde longschade en het bewerkstelligen 
van cardiovasculaire stabiliteit, wordt beschreven. Vervolgens wordt uitgelegd welke 3 
belangrijkste routes betrokken zijn bij de regulatie van de pulmonale vaatweerstand en 
welke medicamenten op de verschillende stappen van de route aangrijpen. Als laatste 
worden kort de mortaliteit, de morbiditeit en de lange-termijn follow-up besproken. 
Deel II Predictie
Hoofdstuk 2 bevat een editorial over een nieuwe postnatale predictor in CHD patiënten, 
het preoperatief meten van de longomtrek op een anterior-posterior genomen 
röntgenfoto (CRTA). De rol van CRTA wordt besproken en in het breder perspectief van 
predictiemodellen voor CHD patiënten geplaatst. Deze nieuwe predictor lijkt een vrij 
betrouwbaar nieuw instrument, maar dient nog extern gevalideerd te worden. Veel 
instrumenten die gebruikt worden voor deze groep patiënten kennen dezelfde problemen; 
ze zijn alleen getest in kleine groepen patiënten, ze zijn moeilijk toe te passen of hebben 
geen gestandaardiseerde definitie of meetmethode. Dit laatste geldt bijvoorbeeld voor 
zowel PH als de O/E LHR, wat de betrouwbaarheid van deze parameters vermindert.
In Hoofdstuk 3 wordt de “Congenital Diaphragmatic Hernia Study Group prediction 
rule”, of het CDHSG predictiemodel, gevalideerd in een cohort van 343 CHD patiënten die 
geboren zijn in 4 Europese centra. Dit model is een vroege voorspeller van mortaliteit in 
CHD patiënten. Alle centra gebruiken hetzelfde CDH-EURO Consortium behandelprotocol. 
In deze groep blijkt het model een redelijke voorspellende waarde te hebben. Om 
het model verder te verbeteren worden de pre- en postnatale gegevens van 620 CHD 
patiënten gebruikt om het model aan te passen. Interessant genoeg blijkt alleen de 
herniatie van de lever in de thorax van additionele waarde te zijn om het predictiemodel 
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te verbeteren. Daarnaast wordt de variabel “ afwezige Apgar score” uit het model gehaald, 
omdat het in onze populatie geen significante bijdrage aan het model levert. 
Als vervolg op de ontdekking van de nieuwe vroege biomarkers SIGLEC-14, BCAM, en 
ANGPTL3 als voorspellers van bronchopulmonale dysplasie (BPD) in premature kinderen, 
worden deze biomarkers getest in prematuren, CHD patiënten en volwassenen in 
Hoofdstuk 4. De rol van deze biomarkers in het voorspellen van BPD in prematuren wordt 
gevalideerd en plasmaconcentraties van de biomarkers correleren in deze groep ook met 
de duur van mechanische beademing, zuurstoftoediening en structurele longafwijkingen. 
Alhoewel chronisch longlijden in CHD patiënten niet kan worden voorspeld, differentieert 
het wel tussen de CHD patiënten die overleven en die overlijden. Daarnaast lijkt 
SIGLEC-5/14 een voorspeller van PH. In volwassenen kan met behulp van de biomarkers 
geen onderscheid worden gemaakt tussen patiënten en gezonde controles. 
Deel III Behandeling
In Hoofdstuk 5 wordt een nieuwe, meer geïndividualiseerde benadering van 
pasgeborenen met CHD in de verloskamers beschreven. In tegenstelling tot voorheen 
worden pasgeborenen met milde CHD, gedefinieerd als geïsoleerde linkszijdige CHD, O/E 
LHR ≥50% en intra-abdominale leverpositie, niet standaard geïntubeerd in de verloskamer, 
maar alleen als ze respiratoir falen ontwikkelen. Deze benadering is succesvol in 40% van 
de patiënten, waarmee mogelijk iatrogene complicaties van het direct intuberen worden 
verminderd. Daarnaast lijkt het geen negatief effect te hebben op de patiënten die 
respiratoir falen ontwikkelen.
Om een geschikt doseringsadvies voor intraveneus sildenafil bij CHD patiënten te 
ontwikkelen, wordt in Hoofdstuk 6 een farmacokinetisch model ontwikkeld met behulp 
van bloedmonsters van 23 zuigelingen met CHD. De verdeling van sildenafil kan worden 
beschreven met een twee-compartimentenmodel en desmethylsildenafil met een 
een-compartimentmodel. Alleen postnatale leeftijd verhoogt de klaring van sildenafil 
en sildenafil wordt goed verdragen in deze relatief kleine groep. Het vaak gebruikte 
doseringsadvies van 0.4mg/kg in 3 uur, gevolgd door 1.6mg/kg/dag middels continue 
toediening, zorgt voor adequate plasmaspiegels van sildenafil in CHD patiënten. 
Het hieraan gerelateerde studieprotocol van de CoDiNOS studie wordt besproken in 
Hoofdstuk 7. De CoDiNOS studie is een internationale gerandomiseerde studie waarbij 
intraveneus sildenafil wordt vergeleken met de inhalatie van stikstofoxide (iNO) als eerste 
stap van de behandeling van PH in neonaten met CHD. De hypothese is dat intraveneus 
sildenafil superior is ten opzichte van iNO. De primaire uitkomst is de afwezigheid van PH 
bij echocardiografische evaluatie op dag 14, zonder behandeling op dag 14 en zonder 
falen van de behandeling eerder, danwel overlijden binnen de eerste 28 dagen van het 
Summary     |   159 
9
leven. Met een steekproefomvang van 330 patiënten zullen we een relatief verschil van 
25% in uitkomst tussen de twee therapieën kunnen vinden. Secundaire uitkomstmaten 
zijn onder andere de noodzaak tot extracorporale membraan oxygenatie, duur van 
behandeling met interventiemedicatie, de incidentie van chronische longziekte en de 
externe validatie van het in hoofdstuk 6 beschreven pharmacokinetische model van 
sildenafil.   
Deel IV Discussie en samenvatting
De discussie van dit proefschrift beschrijft de associatie van dit onderzoek met de 
beschikbare literatuur alsook de implicaties voor verder onderzoek in CHD en zeldzame 
ziektes in het algemeen. De kracht en zwaktes van het onderzoek worden bediscussieerd. 
De belangrijkste aanbevelingen zijn:
- Standaardisatie van meetmethodes en rapportering van verschillende prenatale en 
postnatale parameters is dringend nodig, voor predictie maar ook voor de evaluatie van 
behandelingen.
- Hoewel de rol van predictiemodellen in de postnatale behandeling van CHD patienten 
beperkt is op dit moment, zou patiënt selectie gebaseerd op predictie scores potentieel 
de uitkomst kunnen verbeteren en zorgen voor meer geïndividualiseerde zorg. Het kan 
overbehandeling voorkomen in patienten met milde CHD en het zou een rol kunnen 
hebben in preventie en vroege behandeling in de ernstige casussen. 
- Multicenter onderzoekssamenwerking is essentieel in zeldzame ziektes zoals CHD. Maar 
een RCT in deze populatie blijft een grote uitdaging. Nieuw ontwikkelde statistische 
technieken worden op dit moment niet gebruikt in klinisch onderzoek. Deze technieken 
kunnen het aantal benodigde patienten om de onderzoeksvraag te beantwoorden, fors 
verlagen en zouden dus verder onderzocht en geïmplementeerd dienen te worden. 
- De behandeling van ventriculaire disfunctie dient beter onderzocht te worden, met en 
zonder pulmonale hypertensie, aangezien de behandeling van pulmonale hypertensie de 
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LIST OF ABBREVIATIONS
ALAT  alanine transaminase
ANGPTL3 angiopoietin-like protein 3
ASAT  aspartate transaminase
AUC  area under the curve
BCAM  basal cell adhesion molecule
BPD   bronchopulmonary dysplasia
CDH  congenital diaphragmatic hernia
CDHSG  Congenital Diaphragmatic Hernia Study Group
cGMP  cyclic guanosine monophosphate
CHD  congenitale hernia diafragmatica
CI  confidence interval
CL  clearance
CLD   chronic lung disease
COPD  chronic obstructive pulmonary disease
CRTA  chest radiographic thoracic area
CYP  cytochrome-P-450 enzyme
DMS   desmethylsildenafil
DV  observed concentration
EBC  exhaled breath condensate
ECMO  extracorporeal membrane oxygenation
EDTA  ethylenediamine tetraacetic acid
ELISA  enzyme-linked immunosorbent assay
ERNICA  European Reference Network for rare Inherited and Congenital (digestive 
  and gastrointestinal) Anomalies
FDA  US Food and Drug Administration
FETO  foetal endoscopic tracheal occlusion
FiO2  inspiratory oxygen fraction
FLV  fetal lung volume
FOCE+1  first-order conditional estimation method with interaction
HsTnT  High-sensitivity troponin T
GA  gestational age
GTP  guanosine-5’-triphosphate
IIV  inter-individual variability
iNO  inhaled nitric oxide
IOV  inter occasion variability
IPF  idiopathic pulmonary fibrosis
IPRED  predicted concentration
IQR  interquartile range
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IRB   institutional review board
kPa  kilopascal
LC-MS  liquid chromatography-mass spectrometry
LHR  lung-to-head ratio
LV  left ventricle 
MCA  multiple congenital anomalies
mPAP  mean pulmonary artery pressure
MRI  magnetic resonance imaging
NPDE  normalized prediction distribution errors
NONMEM Nonlinear mixed effects modelling 
NT-proBNP N-terminal pro-brain natriuretic peptide
O/E LHR  observed-to-expected lung-to-head ratio
OI  oxygenation index
PaO2  partial pressure of oxygen
PaCO2  partial pressure of carbon dioxide 
PDE3/5  selective phosphodiesterase type 3/5
PEA  proximity extension assay
PH  pulmonary hypertension
PHT  pulmonary hypertension
PK  pharmacokinetic
PKPD  pharmacokinetic pharmacodynamic 
PPHN  persistent pulmonary hypertension of the newborn
PPM  parts per million
RCT  randomized controlled trial
ROC  receiver operating characteristic
RV  right ventricle
SAE  serious adverse event
SIGLEC-14 sialic acid binding Ig-like lectin 14
SNAP II score Score for Neonatal Physiology version II
sRAGE  soluble receptor for advanced glycation end products
SUSAR  suspected unexpected serious adverse event
TGF- β  transforming growth factor beta
TFLV  total fetal lung volume
US  ultrasound
V   volume of distribution 
VA ECMO veno-arterial  extracorporeal membrane oxygenation
VEGFA  vascular endothelial growth factor A
VILI  ventilator induced lung injury
VIS  vasoactive-inotropic score
VPC  visual predictive check
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DANKWOORD
Na 6 jaar en met de hulp van velen is het boekje af. Het voelt niet als een afsluiting, maar een 
nieuwe stap. Dit onderzoek is tot stand gekomen mede dankzij de hulp en medewerking 
van velen. Een aantal van hen wil ik hier graag in het bijzonder bedanken.
Allereerst alle ouders en kinderen met een congenitale hernia diafragmatica die hebben 
meegewerkt aan de verschillende onderzoeken die we hebben verricht en in het bijzonder 
diegene die hebben meegedaan aan de CoDiNOS studie. De periode van de zwangerschap 
en net na de geboorte is erg heftig, ik waardeer en bewonder jullie bereidheid om mee te 
werken enorm. En ik ervaar het als erg bijzonder dat ik vele van jullie heb mogen bijstaan 
in die moeilijke tijd. 
Dan mijn promotoren Prof. Dick Tibboel en Prof. Karel Allegaert. Allereerst Prof. Tibboel, 
beste Dick, toen ik als stafarts op de ICK begon, gaf jij me daarbij een promotietraject 
“cadeau”. Ondanks dat ik mezelf zag als een echte clinicus, heb jij me laten zien hoe 
verrijkend onderzoek doen is en ik ben er enorm van gaan genieten. Door de jaren heen 
heb ik veel van je geleerd; je conceptueel denken over onderzoek, maar ook je praktische 
oplossingen en je loyaliteit aan de mensen binnen het CDH-EURO Consortium. Daarnaast 
heb je me de mogelijkheid gegeven om mijn eigen weg te vinden binnen het onderzoek. 
De grote interesse voor het ziektebeeld hernia diafragmatica delen we en ik hoop van 
harte dat ik ook in de toekomst van je kennis en kunde gebruik mag maken. 
Mijn tweede promotor, Prof. Allegaert, beste Karel, jij bent later aangeschoven, maar was 
vanaf dat moment een enorme steun in het doen van medicamenteus onderzoek bij 
neonaten. Ik bewonder je kennis, je pragmatisme, de snelheid waarmee je je opbouwende 
commentaren naar me terug stuurde en waardeer je eeuwig optimisme. Of om je te 
citeren: “optimism is a moral duty”. Helaas werk je inmiddels met name in Leuven, maar 
ook digitaal was je zeer betrokken. Hopelijk blijven we ook in de toekomst verbonden via 
het onderzoek. 
Mijn steun en toeverlaat in de praktische kant van het doen van onderzoek, Joke Dunk. 
Joke, zonder jou was de CoDiNOS studie heel wat moeizamer van de grond gekomen. 
Ik waardeer je enorme betrokkenheid, je gedrevenheid en je punctualiteit. Je laat je 
door niks of niemand van je stuk brengen en weet waar je over praat. Dank dat ik op elk 
moment van de dag op je terug kon vallen als het even niet liep en dank voor al praktische 
ideeën en oplossingen. Ellen, dank voor je punctualiteit en doorzettingsvermogen. Ook jij 
hebt me heel wat werk uit handen genomen.  
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thanks to Neil Patel and Florian Kipfmueller, for their vision on CDH and the heart, but also 
for the pleasant meetings we had all over the world. Irma Capolupo, thank you for your 
very warm welcome in Rome, I have enjoyed it so much. Prof Anne Debeer, dank voor het 
warme welkom in Leuven, altijd goed elkaar tegen het lijf te lopen. Dr Arno van Heijst, 
beste Arno, ooit begon dit avontuur bij jou, als jonge AGNIO op de NICU in 2015. Heel veel 
dank voor je steun en wijze woorden, toen en nu. Prof. Thomas Schaible, thank you for 
inviting us to Mannheim and showing us your vision on CDH. I feel privileged that you are 
a member of the committee. Prof. Anne Greenough, thank you for your endless effort to 
get the CoDiNOS trial approved in the UK, unfortunately is was a mission impossible. I am 
honored that you are a member of the committee. 
Alle co-auteurs, hartelijk dank voor de prettige samenwerking. Prof. Irwin Reiss, dank voor 
je bereidheid om de rol van secretaris in de kleine commissie op je te nemen. Dank ook 
voor je hulp en adviezen door de jaren heen, ik kom zeker nog eens binnenwaaien om 
te sparren. Een speciale dank voor Özge, wat geweldig dat ik met je samen kon werken, 
je bent een hele goede onderzoeker en een fijn mens. Ik ben ervan overtuigd dat je een 
geweldige arts zult worden. Joost, bedankt voor je statistisch beredeneren en hopelijk 
krijgt ons project vervolg. Birgit, ik vond het erg prettig met je samen te werken, je maakte 
farmacologie net wat minder gecompliceerd. Ons artikel voelde als een goed 1-2tje tussen 
onze werelden. 
Mijn paranimfen, Maayke Hunfeld en Ulrike Kraemer, wat fijn dat jullie aan mijn zijde 
willen staan. Maayke, mijn fiets- en hardloopmaatje maar ook mijn uitlaatklep en mijn 
promotie-partner in crime. Als het even niet liep, kon ik altijd even spuien bij jou. Dank 
voor je luisterend oor! Hoog tijd om bootje te gaan varen met de kids! Ulrike, wat is het 
toch gezellig om met jou samen te werken. Je bent enthousiast en enorm gemotiveerd 
om mij te helpen bij de CoDiNOS trial, tijdens zwangerschapsverlof, vakantie, maar ook 
als het over het cardiale deel van de studie gaat. Ik ben je enorm dankbaar voor je hulp. 
Collega’s van de ICK, artsen, verpleegkundig specialisten en verpleging, dank voor jullie 
luisterend oor, jullie hulp bij de inclusies voor het onderzoek en de tijd die ik kreeg om 
te schrijven. In het bijzonder wil ik Prof. Matthijs de Hoog bedanken, mijn opleider vanaf 
het eerste Rotterdamse uur tot aan mijn stafplek. Je coachende woorden hebben me 
gebracht waar ik vandaag sta. Ik kwam en kom altijd wijzer je kamer uit, met het gevoel 
dat ik het toch zelf bedacht heb. Sascha, mijn kamergenoot, ik waardeer het sparren over 
de kliniek en het onderzoek enorm, maar ook keuvelen over de kinderen, lekker eten en 
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ons bootje. Ook jij hebt me door de jaren soms door dit onderzoek heen gesleept en 
dingen teruggebracht tot de essentie. 
Mijn lieve vriendinnen; Raffy en Marieke, wat fijn dat we nog zo close zijn, na al die jaren 
en met zoveel kilometers en landsgrenzen tussen ons. Kalinka, Elke, Margit, Marloes, Ylva 
en Esther, hoog tijd voor een Pink Power lustrumreis! El, verras ons! Ik kan niet wachten. 
Janneke en Tanya, wat heerlijk om met jullie te borrelen en jullie perspectief van ons vak 
te horen, we gaan snel Zaltbommel weer onveilig maken. Alle vrienden en vriendinnen 
van Fad Fundum, jullie zijn me dierbaar, we gaan snel weer een weekend op pad. Guido en 
Benedicte, wat mooi om met onze gezinnen op te trekken, daar kan ik echt van genieten. 
Lieve Ruud en Jon, ik kon me geen fijnere schoonouders wensen. We kunnen altijd op 
jullie terugvallen, en het is altijd gezellig. Elke klus wordt door jullie geklaard. Hoog tijd om 
weer eens naar het huisje in Frankrijk te rijden. 
Lieve pap en mam, ondanks dat het medische en academische wereldje ver van jullie bed 
is, hebben jullie altijd achter mijn vele plannen gestaan. Al vroeg hebben jullie me geleerd 
dat je uit het leven moet halen wat erin zit, en dat je daarvoor soms hard moet werken. 
En die wijsheid heeft me hier gebracht, dank daarvoor! Marjon, Mark en Eric, jullie kunnen 
je niks bij mijn fascinatie voor de geneeskunde voorstellen, en dat maakt het juist mooi 
om een zus en broers zoals jullie te hebben. En waar het ook over gaat, het glas is in ieder 
geval altijd half vol. Noëlle, heel erg bedankt voor de prachtige lay-out van mijn boekje!
Lieve Timo, ook deze stap hebben we weer gezet, samen. Ons vak is onmogelijk zonder 
een goed fundament om rust te vinden en om zo af en toe op te leunen. En jij bent zoveel 
meer dan mijn fundament, het leven is mooi samen, dankjewel. En nu is het tijd voor jouw 
plannen. Lieve Tessel, Faas en Pelle, wat is het leven toch bijzonder met jullie erbij. We 
gaan taart bakken!        
